<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Glucose targets for preventing diabetic kidney disease and its progression - Ruospo, M - 2017 | Cochrane Library</title> <meta content="Glucose targets for preventing diabetic kidney disease and its progression - Ruospo, M - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010137.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Glucose targets for preventing diabetic kidney disease and its progression - Ruospo, M - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010137.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010137.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Glucose targets for preventing diabetic kidney disease and its progression" name="citation_title"/> <meta content="Marinella Ruospo" name="citation_author"/> <meta content="Valeria M Saglimbene" name="citation_author"/> <meta content="Diaverum" name="citation_author_institution"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="Salvatore De Cosmo" name="citation_author"/> <meta content="Scientific Institute CSS" name="citation_author_institution"/> <meta content="Antonio Pacilli" name="citation_author"/> <meta content="Scientific Institute CSS" name="citation_author_institution"/> <meta content="Olga Lamacchia" name="citation_author"/> <meta content="University of Foggia" name="citation_author_institution"/> <meta content="Mauro Cignarelli" name="citation_author"/> <meta content="University of Foggia" name="citation_author_institution"/> <meta content="Paola Fioretto" name="citation_author"/> <meta content="University of Padova" name="citation_author_institution"/> <meta content="Mariacristina Vecchio" name="citation_author"/> <meta content="Danone Research" name="citation_author_institution"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="giovanni.strippoli@uniba.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD010137.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010137.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010137.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010137.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Albuminuria [epidemiology]; *Blood Glucose; Cardiovascular Diseases [mortality, prevention &amp; control]; Cause of Death; Creatinine [blood]; Death, Sudden [epidemiology]; Diabetes Mellitus, Type 1 [complications]; Diabetes Mellitus, Type 2 [complications]; Diabetic Nephropathies [blood, *prevention &amp; control]; Disease Progression; Fasting [*blood]; *Glycated Hemoglobin [analysis]; Hyperglycemia [blood, drug therapy]; Hypoglycemic Agents [therapeutic use]; Kidney Failure, Chronic [blood, etiology, *prevention &amp; control]; Myocardial Infarction [mortality, prevention &amp; control]; Randomized Controlled Trials as Topic; Stroke [epidemiology, prevention &amp; control]; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010137.pub2&amp;doi=10.1002/14651858.CD010137.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="18M35a5z";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010137\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010137\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010137.pub2",title:"Glucose targets for preventing diabetic kidney disease and its progression",firstPublishedDate:"Jun 8, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010137.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010137.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010137.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010137.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010137.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010137.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010137.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010137.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010137.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010137.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6962 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010137.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-sec-0098"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/appendices#CD010137-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/table_n/CD010137StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/table_n/CD010137StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Glucose targets for preventing diabetic kidney disease and its progression</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0002">Marinella Ruospo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0003">Valeria M Saglimbene</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0004">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0005">Salvatore De Cosmo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0006">Antonio Pacilli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0007">Olga Lamacchia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0008">Mauro Cignarelli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0009">Paola Fioretto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0010">Mariacristina Vecchio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0011">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information#CD010137-cr-0012"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information/en#CD010137-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010137.pub2">https://doi.org/10.1002/14651858.CD010137.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010137-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010137-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010137-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010137-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010137-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010137-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010137-abs-0001" lang="en"> <section id="CD010137-sec-0001"> <h3 class="title" id="CD010137-sec-0001">Background</h3> <p>Diabetes is the leading cause of end‐stage kidney disease (ESKD) around the world. Blood pressure lowering and glucose control are used to reduce diabetes‐associated disability including kidney failure. However there is a lack of an overall evidence summary of the optimal target range for blood glucose control to prevent kidney failure. </p> </section> <section id="CD010137-sec-0002"> <h3 class="title" id="CD010137-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of intensive (HbA1c &lt; 7% or fasting glucose levels &lt; 120 mg/dL versus standard glycaemic control (HbA1c ≥ 7% or fasting glucose levels ≥ 120 mg/dL for preventing the onset and progression of kidney disease among adults with diabetes. </p> </section> <section id="CD010137-sec-0003"> <h3 class="title" id="CD010137-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Specialised Register up to 31 March 2017 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD010137-sec-0004"> <h3 class="title" id="CD010137-sec-0004">Selection criteria</h3> <p>Randomised controlled trials evaluating glucose‐lowering interventions in which people (aged 14 year or older) with type 1 or 2 diabetes with and without kidney disease were randomly allocated to tight glucose control or less stringent blood glucose targets. </p> </section> <section id="CD010137-sec-0005"> <h3 class="title" id="CD010137-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed studies for eligibility and risks of bias, extracted data and checked the processes for accuracy. Outcomes were mortality, cardiovascular complications, doubling of serum creatinine (SCr), ESKD and proteinuria. Confidence in the evidence was assessing using GRADE. Summary estimates of effect were obtained using a random‐effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) and 95% CI for continuous outcomes. </p> </section> <section id="CD010137-sec-0006"> <h3 class="title" id="CD010137-sec-0006">Main results</h3> <p>Fourteen studies involving 29,319 people with diabetes were included and 11 studies involving 29,141 people were included in our meta‐analyses. Treatment duration was 56.7 months on average (range 6 months to 10 years). Studies included people with a range of kidney function. Incomplete reporting of key methodological details resulted in uncertain risks of bias in many studies. Using GRADE assessment, we had moderate confidence in the effects of glucose lowering strategies on ESKD, all‐cause mortality, myocardial infarction, and progressive protein leakage by kidney disease and low or very low confidence in effects of treatment on death related to cardiovascular complications and doubling of serum creatinine (SCr). </p> <p>For the primary outcomes, tight glycaemic control may make little or no difference to doubling of SCr compared with standard control (4 studies, 26,874 participants: RR 0.84, 95% CI 0.64 to 1.11; I<sup>2</sup>= 73%, low certainty evidence), development of ESKD (4 studies, 23,332 participants: RR 0.62, 95% CI 0.34 to 1.12; I<sup>2</sup>= 52%; low certainty evidence), all‐cause mortality (9 studies, 29,094 participants: RR 0.99, 95% CI 0.86 to 1.13; I<sup>2</sup>= 50%; moderate certainty evidence), cardiovascular mortality (6 studies, 23,673 participants: RR 1.19, 95% CI 0.73 to 1.92; I<sup>2</sup>= 85%; low certainty evidence), or sudden death (4 studies, 5913 participants: RR 0.82, 95% CI 0.26 to 2.57; I<sup>2</sup>= 85%; very low certainty evidence). People who received treatment to achieve tighter glycaemic control probably experienced lower risks of non‐fatal myocardial infarction (5 studies, 25,596 participants: RR 0.82, 95% CI 0.67 to 0.99; I<sup>2</sup>= 46%, moderate certainty evidence), onset of microalbuminuria (4 studies, 19,846 participants: RR 0.82, 95% CI 0.71 to 0.93; I<sup>2</sup>= 61%, moderate certainty evidence), and progression of microalbuminuria (5 studies, 13,266 participants: RR 0.59, 95% CI 0.38 to 0.93; I<sup>2</sup>= 75%, moderate certainty evidence). In absolute terms, tight versus standard glucose control treatment in 1,000 adults would lead to between zero and two people avoiding non‐fatal myocardial infarction, while seven adults would avoid experiencing new‐onset albuminuria and two would avoid worsening albuminuria. </p> </section> <section id="CD010137-sec-0007"> <h3 class="title" id="CD010137-sec-0007">Authors' conclusions</h3> <p>This review suggests that people who receive intensive glycaemic control for treatment of diabetes had comparable risks of kidney failure, death and major cardiovascular events as people who received less stringent blood glucose control, while experiencing small clinical benefits on the onset and progression of microalbuminuria and myocardial infarction. The adverse effects of glycaemic management are uncertain. Based on absolute treatment effects, the clinical impact of targeting an HbA1c &lt; 7% or blood glucose &lt; 6.6 mmol/L is unclear and the potential harms of this treatment approach are largely unmeasured. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010137-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010137-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010137-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010137-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010137-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010137-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010137-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010137-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010137-abs-0005" lang="en"> <h3>Glucose targets for preventing diabetic kidney disease and its progression</h3> <p><b>What is the issue?</b> </p> <p>In many parts of the world, diabetes is the most common reason that people experience kidney failure and need treatment with a kidney transplant or dialysis. Disability (blindness, limb loss, kidney failure) due to diabetes is caused by high blood glucose (sugar) levels. An important question is whether extra treatment to control blood glucose levels to near normal can safely prevent the health consequences of diabetes including lower life expectancy and loss of kidney function, without causing problems such as low blood glucose leading to loss of awareness or seizures. Some medical care of diabetes includes careful blood glucose control to low levels (measured by a blood test called the HbA1C) through the use of extra medication and careful blood glucose monitoring with the help of health professionals. </p> <p><b>What did we do?</b> </p> <p>We looked at the evidence for tighter blood glucose control (lower blood glucose in the long term, that is HbA1c &lt; 7% ) compared with less tight blood glucose control (HbA1c &gt; 7%) in people who have either type 1 or type 2 diabetes. Blood glucose was achieved by any sort of treatment including pills or insulin. </p> <p><b>What did we find?</b> </p> <p>Fourteen studies involving 29,319 people with at risk of diabetes complications were included and 11 studies involving 29,141 people were included in our analyses. Tighter blood glucose control generally didn't show any benefits for patients compared to less tight glucose control. There was no difference in the risks for patients on kidney failure, death, or heart disease complications. A very small number of patients (1 in every 1000 treated each year) might avoid a heart attack with more intense blood glucose management. Some patients would expect to have less protein leakage through kidney function although the clinical impact of this benefit is unclear in the long term. The potential problems with treatment, such as side effects and risks of very low blood glucose (hypoglycaemia) were not generally measured in the studies. </p> <p><b>Our conclusions</b> </p> <p>The review concludes that people with diabetes receive uncertain benefits from tighter blood glucose control in the long‐term and the immediate complications of this treatment approach are difficult to know accurately. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010137-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010137-sec-0098"></div> <h3 class="title" id="CD010137-sec-0099">Implications for practice</h3> <section id="CD010137-sec-0099"> <p>Tight glycaemic control confers little clinically important benefit and uncertain adverse outcomes for people with diabetes. Targeting an HbA1c below 7% might prevent zero to two people experiencing a nonfatal myocardial infarction and result in clinically uncertain effects on death and risks of ESKD during four to eight years of treatment. The effects of tight glucose control on kidney function is unknown and limited to altering albumin excretion, a disease marker of uncertain clinical relevance. While treatment benefits are uncertain, it is possible this is because studies were not sufficiently long (5 to 10 years) to capture the long‐term risks of death and ESKD with diabetes which tend to accrue at 10 to 20 years after diagnosis. Tight glycaemic control may incur important treatment‐related complications (seen in other similar systematic reviews) that may alter the risk‐benefit trade‐off that patients make when considering treatment. Currently, there is insufficient evidence that clinicians and policy‐makers should adopt widespread intensive glycaemic control for patients with diabetes. </p> </section> <h3 class="title" id="CD010137-sec-0100">Implications for research</h3> <section id="CD010137-sec-0100"> <p>Although the results of this review are generally inconclusive, it is unlikely that future similar studies will change our understanding of tight glycaemic control on risks of kidney failure as this endpoint is very rare and large studies would be needed to ascertain true treatment effects. In the context of limited research funding it is unlikely that future large‐scale studies will be conducted. New study ethology such as the registry‐based study might be an appropriate setting for a large‐scale glycaemic control study but despite highly‐efficient study methods, it is still unlikely that ongoing studies will address the question of glycaemic control on patient‐level outcomes. Additional studies that principally measure treatment effects on surrogate outcomes such as albuminuria are not clinically meaningful. Future standardisation of study outcomes that prioritise patient‐important endpoints will facilitate the comparability and design of future studies to assess meaningful treatment effects. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010137-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010137-sec-0029"></div> <div class="table" id="CD010137-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tight glycaemic control compared with non‐tight control for preventing diabetic kidney disease (DKD) and its progression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tight glycaemic control compared with non‐tight control for preventing DKD and its progression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with diabetes </p> <p><b>Intervention:</b> tight glycaemic control </p> <p><b>Comparison:</b> non‐tight glycaemic control </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Confidence of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Non‐tight control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tight control</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Doubling serum creatinine</b> </p> <p>8.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>39 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>33 per 1000</b> (24.95 to 43.29) </p> <p><b>NNT: 167</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.84</b> (0.64 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26,874 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision (‐1)</p> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ESKD</b> </p> <p>5.9 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> (1.02 to 3.36) </p> <p><b>NNT: 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> (0.34 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,332 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Imprecision (‐1)</p> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sudden death</b> </p> <p>4.6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> (0.52 to 5.14) </p> <p><b>NNT: 0</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> (0.26 to 2.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5,913 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation (‐1)</p> <p>Imprecision (‐1)</p> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>5.6 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> (13.76‐18.08) </p> <p><b>NNT: 0</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> (0.86 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,094 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Imprecision (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>4.4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> (6.57 to 17.28) </p> <p><b>NNH: 500</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> (0.73 to 1.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,673 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Imprecision (‐1)</p> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction</b> </p> <p>5.6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> (5.36 to 7.92) </p> <p><b>NNT: 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> (0.67 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,596 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Onset microalbuminuria</b> </p> <p>5.4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> (35.42 to 43.24) </p> <p><b>NNT: 143</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> (0.77 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,933 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression of microalbuminuria</b> </p> <p>5.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> (1.52 to 3.72) </p> <p><b>NNT: 500</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> (0.38 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,266 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is calculated from data in the meta‐analyses. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence Interval; <b>RR:</b> Risk Ratio; <b>NNT:</b> Number Needed to Treat; <b>NNH:</b> Number Needed to Harm. </p> <p>We did not downgrade for reason of publication bias as insufficient studies contributed to treatment estimates to draw meaningful conclusions </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High confidence:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate confidence:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low confidence:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low confidence:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ESKD ‐ end‐stage kidney disease</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010137-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010137-sec-0030"></div> <section id="CD010137-sec-0031"> <h3 class="title" id="CD010137-sec-0031">Description of the condition</h3> <p>The prevalence of diabetes is increasing worldwide (<a href="./references#CD010137-bbs2-0029" title="International Diabetes Federation. IDF Diabetes atlas (7th edition), 2015. www.diabetesatlas.org/ (accessed 8 April 2017). ">IDF 2015</a>) and people with type 1 or type 2 diabetes are at high risk for a number of serious health problems, including cardiovascular complications, premature death, end‐stage kidney disease (ESKD), blindness, and limb loss (<a href="./references#CD010137-bbs2-0019" title="Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (accessed 8 April 2017). ">CDC 2011</a>). Diabetes is estimated to cause 43 million people around the world to live with disability each year (<a href="./references#CD010137-bbs2-0033" title="MurrayCJ , VosT , LozanoR , NaghaviM , FlaxmanAD , MichaudC , et al. Disability‐adjusted life years(DALYs) for 291 diseases and injuries in 21 regions, 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010.[Erratum appears in Lancet. 2013 Feb 23;381(9867):628 Note: AlMazroa, Mohammad A [added]; Memish, Ziad A [added]]. Lancet2012;380(9859):2197‐223. [MEDLINE: 23245608] ">Murray 2012</a>). </p> <p>Diabetic kidney disease (DKD), which refers to kidney disease caused by diabetes (also called diabetic nephropathy), is the leading cause of people experiencing ESKD. In the USA alone, diabetes is responsible for 44% of people needing treatment with dialysis or transplantation (<a href="./references#CD010137-bbs2-0041" title="US Renal DataSystem . USRDS 2011 Annual Data Report: Atlas of End‐Stage Renal Disease in the United States. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2011. www.usrds.org/atlas11.aspx (accessed 8 April 2017). ">USRDS 2011</a>). Diabetes mellitus affects 3% to 4% of adults worldwide, with prevalence projected to double over the first three decades of the 21st century (<a href="./references#CD010137-bbs2-0043" title="WildS , RoglicG , GreenA , SicreeR , KingH . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care2004;27(5):1047‐53. [MEDLINE: 15111519] ">Wild 2004</a>). Chronic kidney disease (CKD) generally occurs in 25&amp; to 40% of patients with diabetes within 20 to 25 years of onset (<a href="./references#CD010137-bbs2-0037" title="RitzE , OrthSR . Nephropathy in patients with type 2 diabetes mellitus. New England Journal of Medicine1999;341(15):1127‐33. [MEDLINE: 10511612] ">Ritz 1999</a>) but although its incidence has decreased, diabetes is still the most important cause of ESKD in industrialised countries (<a href="./references#CD010137-bbs2-0042" title="US Renal DataSystem . 2013 atlas of CKD and ESRD. www.usrds.org/atlas13.aspx (accessed 8 April 2017). ">USRDS 2013</a>). Recent data have shown a reduction of the incidence of DKD in patients whose diagnosis occurred in more recent years, indicating a most favourable prognosis of type 1 diabetes when diagnosed in the early years, and a lower incidence of ESKD (<a href="./references#CD010137-bbs2-0022" title="FinneP , ReunanenA , StenmanS , GroopPH , Grönhagen‐RiskaC . Incidence of end‐stage renal disease in patients with type 1 diabetes. JAMA2005;294(14):1782‐7. [MEDLINE: 16219881] ">Finne 2005</a>), Similar studies also suggest that early‐onset type 2 diabetes mellitus is associated with substantially increased incidence of ESKD and mortality in middle age (<a href="./references#CD010137-bbs2-0036" title="PavkovME , BennettPH , KnowlerWC , KrakoffJ , SieversML , NelsonRG . Effect of youth‐onset type 2 diabetes mellitus on incidence of end‐stage renal disease and mortality in young and middle‐aged Pima Indians. JAMA2006;26(296):421‐6. [MEDLINE: 16868300] ">Pavkov 2006</a>). </p> </section> <section id="CD010137-sec-0032"> <h3 class="title" id="CD010137-sec-0032">Description of the intervention</h3> <p>The risk of kidney disease among people with diabetes is associated with blood glucose control (<a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>; <a href="./references#CD010137-bbs2-0031" title="KrolewskiAS , LaffelLM , KrolewskiM , QuinnM , WarramJH . Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin‐dependent diabetes mellitus. New England Journal of Medicine1995;332(19):1251‐5. [MEDLINE: 7708068] ">Krolewski 1995</a>; <a href="./references#CD010137-bbs2-0040" title="UK Prospective Diabetes Study Group. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug 14;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] ">UKPDS 1998</a>). Consequently, the role of tight glycaemic control (glycated haemoglobin (HbA1c) &lt; 7% or fasting glucose levels &lt; 120 mg/dL (6.7 mmol/L)) on the onset and progression of DKD has been explored by several randomised controlled trials (RCTs) in patients with type 1 (<a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>) and type 2 (<a href="./references#CD010137-bbs2-0030" title="Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] ">Ismail 2010</a>; <a href="./references#CD010137-bbs2-0032" title="MoritzT , DuckworthW , AbrairaC . Veterans affairs diabetes trial ‐ corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024–5. [MEDLINE: 19726779] ">Moritz 2009</a>; <a href="./references#CD010137-bbs2-0034" title="ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ">Patel 2008</a>; <a href="./references#CD010137-bbs2-0040" title="UK Prospective Diabetes Study Group. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug 14;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] ">UKPDS 1998</a>) diabetes. These studies have specifically compared the effect of more intensive treatment to target lower fasting plasma glucose levels or HbA1c on kidney outcomes compared with conventional hypoglycaemic therapy. </p> <p>While there is an association between higher blood glucose levels and poorer clinical outcomes among people with diabetes, the impact of glucose‐lowering treatment to tighter glucose treatment targets remains uncertain and potential harms including hypoglycaemia are increased. A meta‐analysis of tight blood glucose control showed that people receiving intensive antihyperglycaemic treatment had similar risks of all‐cause mortality and cardiovascular mortality as people with conventional blood glucose targets and insufficient information was available in accrued clinical studies to evaluate benefits of tighter glycaemia targets on non‐fatal myocardial infarction, composite microvascular complications, or retinopathy (<a href="./references#CD010137-bbs2-0026" title="HemmingsenB , LundSS , Gluud C , VaagA , Almdal T , Hemmingsen C , et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta‐analysis and trial sequential analysis of randomised clinical trials. BMJ2011;343:d6898. [MEDLINE: 22115901] ">Hemmingsen 2011</a>), while people allocated to lower blood glucose levels experienced a 30% increased risk of severe hypoglycaemia. </p> </section> <section id="CD010137-sec-0033"> <h3 class="title" id="CD010137-sec-0033">How the intervention might work</h3> <p>Hyperglycaemia is a crucial factor in the development of DKD due to tissue glycosylation including glomerular and mesangial cells. Three mechanisms have been postulated that explain pathways of glucose‐mediated tissue damage: non‐enzymatic glycosylation that generates advanced glycosylation end products; activation of protein kinase C (PKC); and acceleration of the aldose reductase pathway. RCTs have shown that people receiving tight glycaemic control experience less new microalbuminuria, while the impact of tighter glucose targets on the progression from microalbuminuria to overt kidney failure (doubling serum creatinine (SCr) and ESKD), remains unclear. Conflicting results on the role played by tight glycaemic control on cardiovascular events and total mortality among people with kidney disease have been reported (<a href="./references#CD010137-bbs2-0021" title="DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenPD , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] ">Duckworth 2009</a>; <a href="./references#CD010137-bbs2-0034" title="ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ">Patel 2008</a>), with a recent study showing an increased risk of death associated with intensive glucose treatment (<a href="./references#CD010137-bbs2-0023" title="Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] ">Gerstain 2008</a>). Hypoglycaemia is the major risk of intensive glucose treatment and a higher rate of severe hypoglycaemia has been consistently reported with tight glucose control (<a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>; <a href="./references#CD010137-bbs2-0040" title="UK Prospective Diabetes Study Group. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug 14;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] ">UKPDS 1998</a>). Although mild episodes generally may be well tolerated, severe hypoglycaemia can cause serious injury, unconsciousness, seizures, coma, myocardial ischaemia, angina, residual neurological impairment, or death (<a href="./references#CD010137-bbs2-0020" title="DesouzaC , SalazarH , CheongB , MurgoJ , FonsecaV . Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care2003;26(5):1485‐9. [MEDLINE: 12716809] ">Desouza 2003</a>). </p> </section> <section id="CD010137-sec-0034"> <h3 class="title" id="CD010137-sec-0034">Why it is important to do this review</h3> <p>The benefits and harms of tight versus standard blood glucose control for cardiovascular and kidney‐related outcomes in people with diabetes and kidney disease have not been formally summarised in a systematic review. This review attempts to provide this overview of the existing evidence. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010137-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010137-sec-0035"></div> <p>To evaluate the benefits and harms of intensive (HbA1c &lt; 7% or fasting glucose levels &lt; 120 mg/dL versus standard glycaemic control (HbA1c ≥ 7% or fasting glucose levels ≥120 mg/dL for preventing the onset and progression of kidney disease among adults with diabetes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010137-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010137-sec-0036"></div> <section id="CD010137-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010137-sec-0038"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) that evaluated the effect of tight versus standard glycaemic control administered to patients with type 1 or type 2 diabetes with or without kidney disease were included. Studies were included if they reported follow‐up data during treatment of 6 months or longer.    </p> </section> <section id="CD010137-sec-0039"> <h4 class="title">Types of participants</h4> <section id="CD010137-sec-0040"> <h5 class="title">Inclusion criteria</h5> <p>People with type 1 or type 2 diabetes, irrespective of blood pressure (BP) and baseline blood glucose levels </p> <p> <ul id="CD010137-list-0001"> <li> <p>Without kidney disease: defined as a normal estimated (e) or measured (m) glomerular filtration rate (GFR) (&gt; 90 mL/min) and an albumin excretion rate of &lt; 30 mg/d on a timed specimen or urinary albumin/creatinine ratio (ACR) &lt; 30 mg/g confirmed with three serial measurements) </p> </li> <li> <p>With kidney disease</p> <ul id="CD010137-list-0002"> <li> <p>Normal or impaired GFR (&gt; 90 mL/min) with or without microalbuminuria defined as an albumin excretion rate between 30 and 300 mg/d or 20 to 200 μg/min on a timed specimen or urinary ACR between 30 and 300 mg/g, confirmed with three serial measurements </p> </li> <li> <p>Macroalbuminuria defined as an albumin excretion rate ≥ 300 mg/d or ≥ 200 μg/min on a timed specimen or urinary ACR ≥ 300 mg/g, confirmed with three serial measurements. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD010137-sec-0041"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD010137-list-0003"> <li> <p>People with diabetes and CKD not caused by diabetes, as proven by kidney biopsy</p> </li> <li> <p>Children and adolescents aged &lt; 14 years</p> </li> <li> <p>Pregnant women.</p> </li> </ul> </p> </section> </section> <section id="CD010137-sec-0042"> <h4 class="title">Types of interventions</h4> <p>The interventions of interest were tight glycaemic control versus standard glycaemic control. </p> <p>Tight glycaemic control was defined by allocation to a treatment approach targeting an HbA1c &lt; 7% or fasting glucose levels &lt; 120 mg/dL (6.7 mmol/L). </p> <p>Standard (conventional) glycaemic control was defined by allocation to a treatment approach targeting HbA1c ≥ 7% or fasting glycaemic control ≥ 120 mg/dL (6.7 mmol/L) or as defined by the authors, including standard practice clinical care. Three sub‐categories of conventional control (HbA1C: i. 7.0% to 8.5%; ii. 8.5% to 10.0%; iii. &gt; 10.0%) were considered. </p> <p>Glycaemic control could be achieved by any blood glucose‐lowering approach, administered at any dose and for a duration of at least six months. We considered studies in which people were randomly allocated to placebo or standard care (no targeted treatment) and studies that allocated participants to two different treatments or different doses of the same treatment as long as the glucose target was tight versus conventional in the study. </p> </section> <section id="CD010137-sec-0043"> <h4 class="title">Types of outcome measures</h4> <section id="CD010137-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010137-list-0004"> <li> <p>Doubling of SCr</p> </li> <li> <p>ESKD (GFR &lt; 15 mL/min for 3 months or longer, treated with dialysis, transplantation or symptomatic management) </p> </li> <li> <p>Death (any cause, cardiovascular, sudden) or nonfatal myocardial infarction or stroke</p> </li> </ul> </p> </section> <section id="CD010137-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010137-list-0005"> <li> <p>Onset, progression, or regression of microalbuminuria</p> </li> <li> <p>Urinary ACR at the end of treatment or change between beginning and end of treatment</p> </li> <li> <p>SCr (mg/dL, μmol/L) at the end of treatment or change in SCr between beginning and end of treatment </p> </li> <li> <p>Creatinine clearance (CrCl) or GFR (any measure) at the end of treatment or change (any measure) between beginning and end of treatment and change in GFR per year of follow‐up (mL/min/y) </p> </li> <li> <p>Hypoglycaemia defined as:</p> <ol id="CD010137-list-0006"> <li> <p>Minor hypoglycaemia</p> </li> <li> <p>Major hypoglycaemia</p> </li> <li> <p>Serious or severe hypoglycaemia.</p> </li> </ol> </li> <li> <p>Glycaemic control (%HbA1c) at end of treatment or change from beginning to end of treatment and hypoglycaemia (as a dichotomous outcome) defined according to the definitions of individual studies </p> </li> <li> <p>Lipid profile (low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol, triglycerides) at end of treatment and change from beginning to end of treatment. </p> </li> </ul> </p> </section> </section> </section> <section id="CD010137-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010137-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Specialised Register</a> up to 31 March 2017 through contact with the Information Specialist using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from several sources. </p> <p> <ol id="CD010137-list-0007"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD010137-sec-0104">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD010137-sec-0048"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD010137-list-0008"> <li> <p>Reference lists of nephrology textbooks, review articles and relevant studies.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> <li> <p>Conference proceedings from nephrology meetings.</p> </li> </ol> </p> </section> </section> <section id="CD010137-sec-0049"> <h3 class="title" id="CD010137-sec-0049">Data collection and analysis</h3> <section id="CD010137-sec-0050"> <h4 class="title">Selection of studies</h4> <p>The search strategy was used to obtain titles and abstracts of studies that might be relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however, studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts, and if necessary the full text, of these studies to determine which studies satisfied the inclusion criteria. Disagreements in the adjudication of eligible studies was resolved by consensus and discussion with a third author. </p> </section> <section id="CD010137-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard electronic data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was included. Where relevant outcomes are only published in earlier versions these data were used. Any discrepancy between published versions was highlighted. Disagreements in data extraction were resolved by consultation with all authors. </p> </section> <section id="CD010137-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the Cochrane risk of bias assessment tool (<a href="./references#CD010137-bbs2-0028" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (<i>see</i><a href="./appendices#CD010137-sec-0105">Appendix 2</a>). </p> <p> <ul id="CD010137-list-0009"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD010137-list-0010"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD010137-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (doubling of SCr, ESKD, death (any cause), sudden death, death (due to cardiovascular causes), non‐fatal cardiovascular events (myocardial infarction and stroke), onset of microalbuminuria, progression of albuminuria or proteinuria, regression to normoalbuminuria, regression to microalbuminuria, or regression to normoalbuminuria, or adverse effects including hypoglycaemia, the treatment effects were expressed as risk ratios (RR) together with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (urinary albumin excretion, urinary ACR, BP, SCr, CrCl, GFR), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales were used. </p> </section> <section id="CD010137-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p> <ul id="CD010137-list-0011"> <li> <p>Cluster RCTs: we considered cluster studies if they had been appropriately analysed taking into account intra‐class correlation coefficients and relevant data were documented in the report, however, no cluster RCTs were eligible for inclusion </p> </li> <li> <p>Cross‐over studies: no cross‐over studies were eligible for inclusion</p> </li> <li> <p>Studies with multiple treatment groups: studies in which there were more than two treatment arms, data for dichotomous outcomes were combined according to treatment intervention to avoid double‐counting of information. </p> </li> </ul> </p> </section> <section id="CD010137-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>No correspondence was sought from investigators of eligible studies.</p> </section> <section id="CD010137-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. Heterogeneity was then analysed using a Chi<sup>2</sup> test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I<sup>2</sup> test (<a href="./references#CD010137-bbs2-0027" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). A guide to the interpretation of I<sup>2</sup> values is as follows. </p> <p> <ul id="CD010137-list-0012"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I<sup>2</sup> depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>) (<a href="./references#CD010137-bbs2-0028" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010137-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>We generated funnel plots to assess for evidence of small‐study effects for outcomes in which there were data for nine or more studies (<a href="./references#CD010137-bbs2-0028" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010137-sec-0058"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using random‐effects meta‐analysis.</p> </section> <section id="CD010137-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis were prespecified to explore possible sources of heterogeneity (e.g. participants, interventions, and study quality). We assessed for evidence of different treatment effects based on the following characteristics: </p> <p> <ul id="CD010137-list-0013"> <li> <p>Age</p> </li> <li> <p>GFR (≥ 90 mL/min/1.73 m<sup>2</sup> versus &lt; 90 mL/min/1.73 m<sup>2</sup>) </p> </li> <li> <p>Duration of follow‐up (≥ 60 months versus &lt; 60 months)</p> </li> <li> <p>Allocation concealment (low versus unclear risk)</p> </li> </ul> </p> </section> <section id="CD010137-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analyses to explore the influence of the following factors on effect size, although insufficient data were available to complete such analyses. </p> <section id="CD010137-sec-0061"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD010137-bbs2-0038" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD010137-bbs2-0024" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD010137-bbs2-0039" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD010137-list-0014"> <li> <p>Doubling of SCr</p> </li> <li> <p>ESKD</p> </li> <li> <p>Sudden death</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Non‐fatal myocardial infarction</p> </li> <li> <p>Onset microalbuminuria</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010137-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010137-sec-0062"></div> <section id="CD010137-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD010137-sec-0064"> <h4 class="title">Results of the search</h4> <p>The electronic search strategy identified 3348 unique citations. After title and abstract review 3140 records were excluded (not randomised, wrong population, wrong intervention). Of the remaining 208 records, we identified 18 studies; 14 included studies (204 records) (<a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a>; <a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a>; <a href="./references#CD010137-bbs2-0003" title="CiavarellaA , VanniniP , FlamminiM , BacciL , ForlaniG , BorgninoLC . Effect of long‐term near‐normoglycemia on the progression of diabetic nephropathy. Diabete et Metabolisme1985;11(1):3‐8. [MEDLINE: 3884404] ">Ciavarella 1985</a>; <a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>; <a href="./references#CD010137-bbs2-0005" title="Feldt‐RasmussenB , MathiesenER , DeckertT . Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin‐dependent diabetes. Lancet1986;2(8519):1300‐4. [MEDLINE: 2878175] Feldt‐RasmussenB , MathiesenER , HegedusL , DeckertT . Kidney function during 12 months of strict metabolic control in insulin‐dependent diabetic patients with incipient nephropathy. New England Journal of Medicine1986;314(11):665‐70. [MEDLINE: 3513009] ">Feldt‐Rasmussen 1986</a>; <a href="./references#CD010137-bbs2-0006" title="OhkuboY , KishikawaH , ArakiE , MiyataT , IsamiS , MotoyoshiS , et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent diabetes mellitus: a randomized prospective 6‐year study. Diabetes Research &amp; Clinical Practice1995;28(2):103‐17. [MEDLINE: 7587918] ShichiriM , KishikawaH , OhkuboY , WakeN . Long‐term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care2000;23 Suppl 2:B21‐9. [MEDLINE: 10860187] WakeN , HisashigeA , KatayamaT , KishikawaH , OhkuboY , SakaiM , et al. Cost‐effectiveness of intensive insulin therapy for type 2 diabetes: a 10‐year follow‐up of the Kumamoto study. Diabetes Research &amp; Clinical Practice2000;48(3):201‐10. [MEDLINE: 10802159] ">KUMAMOTO Study 1995</a>; <a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a>; <a href="./references#CD010137-bbs2-0008" title="Dahl‐JorgensenK , Brinchmann‐HansenO , HanssenKF , GanesT , KierulfP , SmelandE , et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. British Medical Journal Clinical Research Ed1986;293(6556):1195‐9. [MEDLINE: 3096429] Dahl‐JorgensenK , HanssenKF , KierulfP , BjoroT , SandvikL , AagenaesO . Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin‐dependent diabetes mellitus. The Oslo Study. Acta Endocrinologica1988;117(1):19‐25. [MEDLINE: 3289293] ">OSLO Study 1986</a>; <a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a>; <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a>; <a href="./references#CD010137-bbs2-0011" title="Effect of 6 months of strict metabolic control on eye and kidney function in insulin‐dependent diabetics with background retinopathy. Steno Study Group. Lancet1982;1(8264):121‐4. [MEDLINE: 6119509] ">STENO Study 1982</a>; <a href="./references#CD010137-bbs2-0012" title="Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877‐90. [MEDLINE: 1778353] TurnerR , CullC , HolmanR . United Kingdom Prospective Diabetes Study 17: a 9‐year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non‐insulin‐dependent diabetes mellitus. Annals of Internal Medicine1996;124(1 pt 2):136‐45. [MEDLINE: 8554206] ">UKPDS Study 1991</a>; <a href="./references#CD010137-bbs2-0013" title="AbrairaC , ColwellJ , NuttallF , SawinCT , HendersonW , ComstockJP , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine1997;157(2):181‐8. [MEDLINE: 9009975] AbrairaC , ColwellJA , NuttallFQ , SawinCT , NagelNJ , ComstockJP , et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18(8):1113‐23. [MEDLINE: 7587846] AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , LevinS , et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care1992;15(11):1560‐71. [MEDLINE: 1308130] AbrairaC , HendersonWG , ColwellJA , NuttallFQ , ComstockJP , EmanueleNV , et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care1998;21(4):574‐9. [MEDLINE: 9571345] AbrairaC , McGuireDK . Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal1999;138(5 Pt 1):S360‐5. [MEDLINE: 10539798] AgrawalL , EmanueleNV , AbrairaC , HendersonWG , LevinSR , SawinCT , et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care1998;21(4):510‐5. [MEDLINE: 9571333] AzadN , EmanueleNV , AbrairaC , HendersonWG , ColwellJ , LevinSR , et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes &amp; its Complications1999;13(5‐6):307‐13. [MEDLINE: 10765007] EmanueleN , AzadN , AbrairaC , HendersonW , ColwellJ , LevinS , et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine1998;158(22):2485‐90. [MEDLINE: 9855387] EmanueleN , KleinR , AbrairaC , ColwellJ , ComstockJ , HendersonWG , et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care1996;19(12):1375‐81. [MEDLINE: 8941467] LevinSR , CoburnJW , AbrairaC , HendersonWG , ColwellJA , EmanueleNV , et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care2000;23(10):1478‐85. [MEDLINE: 11023140] PitaleS , Kernan‐SchroederD , EmanueleN , SawinC , SacksJ , AbrairaC , et al. Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes &amp; its Complications2005;19(4):207‐11. [MEDLINE: 15993354] PitaleSU , AbrairaC , EmanueleNV , McCarrenM , HendersonWG , PacoldI , et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care2000;23(9):1316‐20. [MEDLINE: 10977025] ">VA‐CSDM Study 1992</a>; <a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a>), and four excluded studies (four records) (<a href="./references#CD010137-bbs2-0015" title="ChristiansenJS , IngerslevJ , BernvilSS , ChristensenCK , HermansenK , SchmitzA . Near normoglycemia for 1 year has no effect on platelet reactivity, factor VIII, and von Willebrand factor in insulin‐dependent diabetes mellitus: a controlled trial. Journal of Diabetic Complications1987;1(3):100‐6. [MEDLINE: 2969906] ">Christiansen 1987</a>; <a href="./references#CD010137-bbs2-0016" title="HolmanRR , DornanTL , Mayon‐WhiteV , Howard‐WilliamsJ , Orde‐PeckarC , JenkinsL , et al. Prevention of deterioration of renal and sensory‐nerve function by more intensive management of insulin‐dependent diabetic patients. A two‐year randomised prospective study. Lancet1983;1(8318):204‐8. [MEDLINE: 6130244] ">Holman 1983</a>; <a href="./references#CD010137-bbs2-0017" title="KawamoriR , KamadoK , KamadaT . Recent progress in the treatment of diabetic nephropathy: importance of strict glycemic control on the regression of diabetic nephropathy. Journal of Diabetic Complications1991;5(2‐3):88‐90. [MEDLINE: 1770063] ">Kawamori 1991</a>; <a href="./references#CD010137-bbs2-0018" title="WisemanMJ , SaundersAJ , KeenH , VibertiG . Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin‐dependent diabetes. New England Journal of Medicine1985;312(10):617‐21. [MEDLINE: 3883162] ">Wiseman 1985</a>) (<a href="#CD010137-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010137-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD010137-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD010137-sec-0065"> <h4 class="title">Included studies</h4> <p>The 14 included studies enrolled 29,319 participants from Europe and USA published between 1982 and 2011 were included in the systematic review and 11 studies involving 29,141 participants could be included in our meta‐analysis (<a href="./references#CD010137-sec-0109" title="">Characteristics of included studies</a>). Three studies were not included in meta‐analyses as outcome data were not reported in a format that could be extracted for analysis (<a href="./references#CD010137-bbs2-0006" title="OhkuboY , KishikawaH , ArakiE , MiyataT , IsamiS , MotoyoshiS , et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent diabetes mellitus: a randomized prospective 6‐year study. Diabetes Research &amp; Clinical Practice1995;28(2):103‐17. [MEDLINE: 7587918] ShichiriM , KishikawaH , OhkuboY , WakeN . Long‐term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care2000;23 Suppl 2:B21‐9. [MEDLINE: 10860187] WakeN , HisashigeA , KatayamaT , KishikawaH , OhkuboY , SakaiM , et al. Cost‐effectiveness of intensive insulin therapy for type 2 diabetes: a 10‐year follow‐up of the Kumamoto study. Diabetes Research &amp; Clinical Practice2000;48(3):201‐10. [MEDLINE: 10802159] ">KUMAMOTO Study 1995</a>; <a href="./references#CD010137-bbs2-0008" title="Dahl‐JorgensenK , Brinchmann‐HansenO , HanssenKF , GanesT , KierulfP , SmelandE , et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. British Medical Journal Clinical Research Ed1986;293(6556):1195‐9. [MEDLINE: 3096429] Dahl‐JorgensenK , HanssenKF , KierulfP , BjoroT , SandvikL , AagenaesO . Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin‐dependent diabetes mellitus. The Oslo Study. Acta Endocrinologica1988;117(1):19‐25. [MEDLINE: 3289293] ">OSLO Study 1986</a>; <a href="./references#CD010137-bbs2-0011" title="Effect of 6 months of strict metabolic control on eye and kidney function in insulin‐dependent diabetics with background retinopathy. Steno Study Group. Lancet1982;1(8264):121‐4. [MEDLINE: 6119509] ">STENO Study 1982</a>). </p> <p>The mean duration of follow‐up in included studies was 56.7 months (ranging from 6 to 120 months). </p> <p>There were four studies involving 1589 people with type 1 diabetes (<a href="./references#CD010137-bbs2-0003" title="CiavarellaA , VanniniP , FlamminiM , BacciL , ForlaniG , BorgninoLC . Effect of long‐term near‐normoglycemia on the progression of diabetic nephropathy. Diabete et Metabolisme1985;11(1):3‐8. [MEDLINE: 3884404] ">Ciavarella 1985</a>; <a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>; <a href="./references#CD010137-bbs2-0005" title="Feldt‐RasmussenB , MathiesenER , DeckertT . Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin‐dependent diabetes. Lancet1986;2(8519):1300‐4. [MEDLINE: 2878175] Feldt‐RasmussenB , MathiesenER , HegedusL , DeckertT . Kidney function during 12 months of strict metabolic control in insulin‐dependent diabetic patients with incipient nephropathy. New England Journal of Medicine1986;314(11):665‐70. [MEDLINE: 3513009] ">Feldt‐Rasmussen 1986</a>; <a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a>), eight studies involving 27,654 people with type 2 diabetes (<a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a>; <a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a>; <a href="./references#CD010137-bbs2-0006" title="OhkuboY , KishikawaH , ArakiE , MiyataT , IsamiS , MotoyoshiS , et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent diabetes mellitus: a randomized prospective 6‐year study. Diabetes Research &amp; Clinical Practice1995;28(2):103‐17. [MEDLINE: 7587918] ShichiriM , KishikawaH , OhkuboY , WakeN . Long‐term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care2000;23 Suppl 2:B21‐9. [MEDLINE: 10860187] WakeN , HisashigeA , KatayamaT , KishikawaH , OhkuboY , SakaiM , et al. Cost‐effectiveness of intensive insulin therapy for type 2 diabetes: a 10‐year follow‐up of the Kumamoto study. Diabetes Research &amp; Clinical Practice2000;48(3):201‐10. [MEDLINE: 10802159] ">KUMAMOTO Study 1995</a>; <a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a>; <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a>; <a href="./references#CD010137-bbs2-0012" title="Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877‐90. [MEDLINE: 1778353] TurnerR , CullC , HolmanR . United Kingdom Prospective Diabetes Study 17: a 9‐year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non‐insulin‐dependent diabetes mellitus. Annals of Internal Medicine1996;124(1 pt 2):136‐45. [MEDLINE: 8554206] ">UKPDS Study 1991</a>; <a href="./references#CD010137-bbs2-0013" title="AbrairaC , ColwellJ , NuttallF , SawinCT , HendersonW , ComstockJP , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine1997;157(2):181‐8. [MEDLINE: 9009975] AbrairaC , ColwellJA , NuttallFQ , SawinCT , NagelNJ , ComstockJP , et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18(8):1113‐23. [MEDLINE: 7587846] AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , LevinS , et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care1992;15(11):1560‐71. [MEDLINE: 1308130] AbrairaC , HendersonWG , ColwellJA , NuttallFQ , ComstockJP , EmanueleNV , et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care1998;21(4):574‐9. [MEDLINE: 9571345] AbrairaC , McGuireDK . Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal1999;138(5 Pt 1):S360‐5. [MEDLINE: 10539798] AgrawalL , EmanueleNV , AbrairaC , HendersonWG , LevinSR , SawinCT , et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care1998;21(4):510‐5. [MEDLINE: 9571333] AzadN , EmanueleNV , AbrairaC , HendersonWG , ColwellJ , LevinSR , et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes &amp; its Complications1999;13(5‐6):307‐13. [MEDLINE: 10765007] EmanueleN , AzadN , AbrairaC , HendersonW , ColwellJ , LevinS , et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine1998;158(22):2485‐90. [MEDLINE: 9855387] EmanueleN , KleinR , AbrairaC , ColwellJ , ComstockJ , HendersonWG , et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care1996;19(12):1375‐81. [MEDLINE: 8941467] LevinSR , CoburnJW , AbrairaC , HendersonWG , ColwellJA , EmanueleNV , et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care2000;23(10):1478‐85. [MEDLINE: 11023140] PitaleS , Kernan‐SchroederD , EmanueleN , SawinC , SacksJ , AbrairaC , et al. Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes &amp; its Complications2005;19(4):207‐11. [MEDLINE: 15993354] PitaleSU , AbrairaC , EmanueleNV , McCarrenM , HendersonWG , PacoldI , et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care2000;23(9):1316‐20. [MEDLINE: 10977025] ">VA‐CSDM Study 1992</a>; <a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a>), and two studies involving 1665 people who had insulin‐dependent diabetes (<a href="./references#CD010137-bbs2-0008" title="Dahl‐JorgensenK , Brinchmann‐HansenO , HanssenKF , GanesT , KierulfP , SmelandE , et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. British Medical Journal Clinical Research Ed1986;293(6556):1195‐9. [MEDLINE: 3096429] Dahl‐JorgensenK , HanssenKF , KierulfP , BjoroT , SandvikL , AagenaesO . Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin‐dependent diabetes mellitus. The Oslo Study. Acta Endocrinologica1988;117(1):19‐25. [MEDLINE: 3289293] ">OSLO Study 1986</a>; <a href="./references#CD010137-bbs2-0011" title="Effect of 6 months of strict metabolic control on eye and kidney function in insulin‐dependent diabetics with background retinopathy. Steno Study Group. Lancet1982;1(8264):121‐4. [MEDLINE: 6119509] ">STENO Study 1982</a>). </p> <p>The average age of participants was highly variable (ranging between 18 and 66 years). Of the 11 studies contributing outcome data, one study (190 participants) involved people with stage 2 CKD (eGFR 60 to 90 mL/min) (<a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a>), and five studies (11,990 participants) reported treatment in people with stage 1 CKD (eGFR &gt; 90 mL/min/1.73 m<sup>2</sup>) (<a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a>; <a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>; <a href="./references#CD010137-bbs2-0005" title="Feldt‐RasmussenB , MathiesenER , DeckertT . Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin‐dependent diabetes. Lancet1986;2(8519):1300‐4. [MEDLINE: 2878175] Feldt‐RasmussenB , MathiesenER , HegedusL , DeckertT . Kidney function during 12 months of strict metabolic control in insulin‐dependent diabetic patients with incipient nephropathy. New England Journal of Medicine1986;314(11):665‐70. [MEDLINE: 3513009] ">Feldt‐Rasmussen 1986</a>; <a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a>; <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a>). In the remaining studies, the level of kidney function was not specified. </p> <p>Among studies included in our meta‐analyses, five (<a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a>; <a href="./references#CD010137-bbs2-0005" title="Feldt‐RasmussenB , MathiesenER , DeckertT . Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin‐dependent diabetes. Lancet1986;2(8519):1300‐4. [MEDLINE: 2878175] Feldt‐RasmussenB , MathiesenER , HegedusL , DeckertT . Kidney function during 12 months of strict metabolic control in insulin‐dependent diabetic patients with incipient nephropathy. New England Journal of Medicine1986;314(11):665‐70. [MEDLINE: 3513009] ">Feldt‐Rasmussen 1986</a>; <a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a>; <a href="./references#CD010137-bbs2-0013" title="AbrairaC , ColwellJ , NuttallF , SawinCT , HendersonW , ComstockJP , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine1997;157(2):181‐8. [MEDLINE: 9009975] AbrairaC , ColwellJA , NuttallFQ , SawinCT , NagelNJ , ComstockJP , et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18(8):1113‐23. [MEDLINE: 7587846] AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , LevinS , et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care1992;15(11):1560‐71. [MEDLINE: 1308130] AbrairaC , HendersonWG , ColwellJA , NuttallFQ , ComstockJP , EmanueleNV , et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care1998;21(4):574‐9. [MEDLINE: 9571345] AbrairaC , McGuireDK . Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal1999;138(5 Pt 1):S360‐5. [MEDLINE: 10539798] AgrawalL , EmanueleNV , AbrairaC , HendersonWG , LevinSR , SawinCT , et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care1998;21(4):510‐5. [MEDLINE: 9571333] AzadN , EmanueleNV , AbrairaC , HendersonWG , ColwellJ , LevinSR , et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes &amp; its Complications1999;13(5‐6):307‐13. [MEDLINE: 10765007] EmanueleN , AzadN , AbrairaC , HendersonW , ColwellJ , LevinS , et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine1998;158(22):2485‐90. [MEDLINE: 9855387] EmanueleN , KleinR , AbrairaC , ColwellJ , ComstockJ , HendersonWG , et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care1996;19(12):1375‐81. [MEDLINE: 8941467] LevinSR , CoburnJW , AbrairaC , HendersonWG , ColwellJA , EmanueleNV , et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care2000;23(10):1478‐85. [MEDLINE: 11023140] PitaleS , Kernan‐SchroederD , EmanueleN , SawinC , SacksJ , AbrairaC , et al. Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes &amp; its Complications2005;19(4):207‐11. [MEDLINE: 15993354] PitaleSU , AbrairaC , EmanueleNV , McCarrenM , HendersonWG , PacoldI , et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care2000;23(9):1316‐20. [MEDLINE: 10977025] ">VA‐CSDM Study 1992</a>; <a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a>) compared conventional versus intensive (continuous) therapy (12,333 participants); two studies (<a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a>; <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a>) compared standard care within general practice with intensive multifactorial intervention with behaviour modification or a structured education program (350 participants); two studies (<a href="./references#CD010137-bbs2-0003" title="CiavarellaA , VanniniP , FlamminiM , BacciL , ForlaniG , BorgninoLC . Effect of long‐term near‐normoglycemia on the progression of diabetic nephropathy. Diabete et Metabolisme1985;11(1):3‐8. [MEDLINE: 3884404] ">Ciavarella 1985</a>; <a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>) compared one or two daily insulin injections versus three or more or continuous injections (1,451 participants); one study (<a href="./references#CD010137-bbs2-0012" title="Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877‐90. [MEDLINE: 1778353] TurnerR , CullC , HolmanR . United Kingdom Prospective Diabetes Study 17: a 9‐year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non‐insulin‐dependent diabetes mellitus. Annals of Internal Medicine1996;124(1 pt 2):136‐45. [MEDLINE: 8554206] ">UKPDS Study 1991</a>) compared conventional therapy, primarily with diet alone, versus intensive therapy with sulphonylurea or metformin (3,867 participants) and one study (<a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a>) compared standard glucose control (with target HbA1c levels defined on the basis of local guidelines) versus intensive glucose control, defined as the use of gliclazide plus other drugs (11,140 participants) to target HbA1c ≤ 6.5%. </p> <p>A detailed description of the glucose targets to which participants were randomly allocated is provided in <a href="#CD010137-tbl-0002">Table 1</a>. </p> <div class="table" id="CD010137-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of targets definition</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Tight control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b> Non‐tight control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Treatment </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Cut point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Achieved HbA1c (%)*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Treatment </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Cut point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Achieved HbA1c (%)*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intensive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Target HbA1c &lt; 6.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c &lt; 6.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (6.6 to 7.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c: 7.0% to 7.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c: 7.0% to 7.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6 (7 to 8.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intensive with gliclazide ± metformin, thiazolidinediones, acarbose or insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Target HbA1c≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1C ≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.53 ± 0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional with sulphonylurea other than gliclazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c levels defined by local guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.30 ± 1.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0003" title="CiavarellaA , VanniniP , FlamminiM , BacciL , ForlaniG , BorgninoLC . Effect of long‐term near‐normoglycemia on the progression of diabetic nephropathy. Diabete et Metabolisme1985;11(1):3‐8. [MEDLINE: 3884404] ">Ciavarella 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin infusion (SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 ± 0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2 or 3 daily insulin injections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4 ± 0.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 or more daily insulin injections or insulin infusion (SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prePBG 3.9 to 6.7 mmol/L</p> <p>postPBG &lt; 10 mmol/L</p> <p>HbA1c &lt; 6.05%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prePBG 3.9 to 6.7 mmol/L</p> <p>postPBG &lt; 10 mmol/L</p> <p>HbA1c &lt; 6.05%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 ± NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2 daily insulin injections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No glycosuria, hyperglycaemia and ketonuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No glycosuria hyperglycaemia and ketonuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0005" title="Feldt‐RasmussenB , MathiesenER , DeckertT . Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin‐dependent diabetes. Lancet1986;2(8519):1300‐4. [MEDLINE: 2878175] Feldt‐RasmussenB , MathiesenER , HegedusL , DeckertT . Kidney function during 12 months of strict metabolic control in insulin‐dependent diabetic patients with incipient nephropathy. New England Journal of Medicine1986;314(11):665‐70. [MEDLINE: 3513009] ">Feldt‐Rasmussen 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin infusion (SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FBG levels 5 to 10 mmol/L</p> <p>postPBG morning 4 to 7 mmol/L</p> <p>Avoiding blood glucose levels &lt; 3 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FPG 5 to 10 mmol/L</p> <p>postPBG 4 to 7 mmol/L</p> <p>BG &gt; 3 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (5.9 to 8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional insulin therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PostPBG &lt;15 mmol/L</p> <p>Glucose excretion &lt; 20 g/24h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PostPBG &lt; 15 mmol/L</p> <p>Glucose excretion &lt; 20 g/24h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6 (7.2 to 13.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0006" title="OhkuboY , KishikawaH , ArakiE , MiyataT , IsamiS , MotoyoshiS , et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent diabetes mellitus: a randomized prospective 6‐year study. Diabetes Research &amp; Clinical Practice1995;28(2):103‐17. [MEDLINE: 7587918] ShichiriM , KishikawaH , OhkuboY , WakeN . Long‐term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care2000;23 Suppl 2:B21‐9. [MEDLINE: 10860187] WakeN , HisashigeA , KatayamaT , KishikawaH , OhkuboY , SakaiM , et al. Cost‐effectiveness of intensive insulin therapy for type 2 diabetes: a 10‐year follow‐up of the Kumamoto study. Diabetes Research &amp; Clinical Practice2000;48(3):201‐10. [MEDLINE: 10802159] ">KUMAMOTO Study 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 or more daily insulin injections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycaemic control as close to the FBG &lt; 7.78 mmol/L</p> <p>HbA1c &lt; 7.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FBG &lt; 7.78 mmol/L</p> <p>HbA1c &lt; 7.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 ± 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 or 2 daily injections of intermediate‐acting insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>glycaemic control as close to FBG &lt; 7.78 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPG &lt; 7.78 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 ± 1.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intensive care + structured education program</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c ≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c ≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 ± 1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard care by general practitioner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c ≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c ≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 ± 1.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0008" title="Dahl‐JorgensenK , Brinchmann‐HansenO , HanssenKF , GanesT , KierulfP , SmelandE , et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. British Medical Journal Clinical Research Ed1986;293(6556):1195‐9. [MEDLINE: 3096429] Dahl‐JorgensenK , HanssenKF , KierulfP , BjoroT , SandvikL , AagenaesO . Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin‐dependent diabetes mellitus. The Oslo Study. Acta Endocrinologica1988;117(1):19‐25. [MEDLINE: 3289293] ">OSLO Study 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 or more daily insulin injections or insulin infusion (SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 daily mixed insulin injections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intensive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1 ± 0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5 ± 0.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive multifactorial intervention with behaviour modification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c &lt; 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c &lt; 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care by general practitioner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c &lt; 7.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c &lt; 7.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0011" title="Effect of 6 months of strict metabolic control on eye and kidney function in insulin‐dependent diabetics with background retinopathy. Steno Study Group. Lancet1982;1(8264):121‐4. [MEDLINE: 6119509] ">STENO Study 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insulin infusion (SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PostPBG &lt; 9 mmol/L</p> <p>No glycosuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PostPBG &lt; 9 mmol/L</p> <p>No glycosuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7 ± 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 or more daily injections of insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PostPBG &lt;15 mmol/L</p> <p>Glucose excretion &lt; 20 g/24h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PostPBG &lt; 15mmol/L</p> <p>Glucose excretion &lt; 20 g/24h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 ± 1.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0012" title="Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877‐90. [MEDLINE: 1778353] TurnerR , CullC , HolmanR . United Kingdom Prospective Diabetes Study 17: a 9‐year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non‐insulin‐dependent diabetes mellitus. Annals of Internal Medicine1996;124(1 pt 2):136‐45. [MEDLINE: 8554206] ">UKPDS Study 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive with metformin or sulphonylurea ± metformin or insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPG &lt; 6 mmol/L</p> <p>In insulin‐treated patients, pre‐meal glucose concentrations 4 to 7 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPG &lt; 6 mmol/L</p> <p>prePBG 4 to 7 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (6.2 to 8.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional with diet or metformin ± sulphonylurea or sulphonylurea ± metformin or insulin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintain FPG &lt; 15 mmol/L</p> <p>without symptoms of hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPG &lt; 15 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9 (6.9 to 8.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0013" title="AbrairaC , ColwellJ , NuttallF , SawinCT , HendersonW , ComstockJP , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine1997;157(2):181‐8. [MEDLINE: 9009975] AbrairaC , ColwellJA , NuttallFQ , SawinCT , NagelNJ , ComstockJP , et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18(8):1113‐23. [MEDLINE: 7587846] AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , LevinS , et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care1992;15(11):1560‐71. [MEDLINE: 1308130] AbrairaC , HendersonWG , ColwellJA , NuttallFQ , ComstockJP , EmanueleNV , et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care1998;21(4):574‐9. [MEDLINE: 9571345] AbrairaC , McGuireDK . Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal1999;138(5 Pt 1):S360‐5. [MEDLINE: 10539798] AgrawalL , EmanueleNV , AbrairaC , HendersonWG , LevinSR , SawinCT , et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care1998;21(4):510‐5. [MEDLINE: 9571333] AzadN , EmanueleNV , AbrairaC , HendersonWG , ColwellJ , LevinSR , et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes &amp; its Complications1999;13(5‐6):307‐13. [MEDLINE: 10765007] EmanueleN , AzadN , AbrairaC , HendersonW , ColwellJ , LevinS , et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine1998;158(22):2485‐90. [MEDLINE: 9855387] EmanueleN , KleinR , AbrairaC , ColwellJ , ComstockJ , HendersonWG , et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care1996;19(12):1375‐81. [MEDLINE: 8941467] LevinSR , CoburnJW , AbrairaC , HendersonWG , ColwellJA , EmanueleNV , et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care2000;23(10):1478‐85. [MEDLINE: 11023140] PitaleS , Kernan‐SchroederD , EmanueleN , SawinC , SacksJ , AbrairaC , et al. Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes &amp; its Complications2005;19(4):207‐11. [MEDLINE: 15993354] PitaleSU , AbrairaC , EmanueleNV , McCarrenM , HendersonWG , PacoldI , et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care2000;23(9):1316‐20. [MEDLINE: 10977025] ">VA‐CSDM Study 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intensive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c as close to the normal range as possible (5.1 ± 1% (mean ± 2 SD))</p> <p>Normal mean FSG 4.44 to 6.38 mmol/L</p> <p>Other prePBG &lt; 7.22 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c 5.1% + 1</p> <p>FBG 4.44 to 6.38 mmol/L</p> <p>prePBG &lt; 7.22 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1 ± 0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avoid diabetic symptoms, excessive glycosuria, or overt hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No diabetes, glycosuria or hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive with maximal OHA doses ± insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aiming for HbA1c ≤ 6%</p> <p>A priority is to avoid hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c ≤ 6.0%</p> <p>No hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional with half the maximal OHA doses ± insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avoidance of deterioration of HbA1c 8% to 9% and preventing symptoms of glycosuria, hypoglycaemia, and ketonuria </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c 8% to 9%</p> <p>No glycosuria, hyperglycaemia and ketonuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 (NR)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>*</b> value reported as mean ± SD or median (range) </p> <p>FBG ‐ fasting blood glucose; HbA1c ‐ glycated haemoglobin; NR: not reported; PBG ‐ prandial blood glucose; SC‐ subcutaneous </p> </div> </div> </section> <section id="CD010137-sec-0066"> <h4 class="title">Excluded studies</h4> <p>Four studies that were initially selected after title and abstract review were ineligible after full‐text review because of one of the following reasons: not assessing the outcome of interest (<a href="./references#CD010137-bbs2-0015" title="ChristiansenJS , IngerslevJ , BernvilSS , ChristensenCK , HermansenK , SchmitzA . Near normoglycemia for 1 year has no effect on platelet reactivity, factor VIII, and von Willebrand factor in insulin‐dependent diabetes mellitus: a controlled trial. Journal of Diabetic Complications1987;1(3):100‐6. [MEDLINE: 2969906] ">Christiansen 1987</a>; <a href="./references#CD010137-bbs2-0018" title="WisemanMJ , SaundersAJ , KeenH , VibertiG . Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin‐dependent diabetes. New England Journal of Medicine1985;312(10):617‐21. [MEDLINE: 3883162] ">Wiseman 1985</a>), not targeting HbA1c less than 7% (two studies: <a href="./references#CD010137-bbs2-0016" title="HolmanRR , DornanTL , Mayon‐WhiteV , Howard‐WilliamsJ , Orde‐PeckarC , JenkinsL , et al. Prevention of deterioration of renal and sensory‐nerve function by more intensive management of insulin‐dependent diabetic patients. A two‐year randomised prospective study. Lancet1983;1(8318):204‐8. [MEDLINE: 6130244] ">Holman 1983</a>; <a href="./references#CD010137-bbs2-0017" title="KawamoriR , KamadoK , KamadaT . Recent progress in the treatment of diabetic nephropathy: importance of strict glycemic control on the regression of diabetic nephropathy. Journal of Diabetic Complications1991;5(2‐3):88‐90. [MEDLINE: 1770063] ">Kawamori 1991</a>) (<a href="./references#CD010137-sec-0110" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD010137-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>The risks of bias are summarised in and <a href="#CD010137-fig-0002">Figure 2</a> and <a href="#CD010137-fig-0003">Figure 3</a>. See also <a href="./references#CD010137-sec-0109" title="">Characteristics of included studies</a> for details for each study. </p> <div class="figure" id="CD010137-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010137-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010137-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010137-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010137-sec-0068"> <h4 class="title">Allocation</h4> <section id="CD010137-sec-0069"> <h5 class="title">Sequence generation</h5> <p>Eight studies (57%) reported low risk methods for generation of the random sequence (<a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a>; <a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a>; <a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>; <a href="./references#CD010137-bbs2-0008" title="Dahl‐JorgensenK , Brinchmann‐HansenO , HanssenKF , GanesT , KierulfP , SmelandE , et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. British Medical Journal Clinical Research Ed1986;293(6556):1195‐9. [MEDLINE: 3096429] Dahl‐JorgensenK , HanssenKF , KierulfP , BjoroT , SandvikL , AagenaesO . Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin‐dependent diabetes mellitus. The Oslo Study. Acta Endocrinologica1988;117(1):19‐25. [MEDLINE: 3289293] ">OSLO Study 1986</a>; <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a>; <a href="./references#CD010137-bbs2-0012" title="Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877‐90. [MEDLINE: 1778353] TurnerR , CullC , HolmanR . United Kingdom Prospective Diabetes Study 17: a 9‐year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non‐insulin‐dependent diabetes mellitus. Annals of Internal Medicine1996;124(1 pt 2):136‐45. [MEDLINE: 8554206] ">UKPDS Study 1991</a>; <a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a>; <a href="./references#CD010137-bbs2-0013" title="AbrairaC , ColwellJ , NuttallF , SawinCT , HendersonW , ComstockJP , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine1997;157(2):181‐8. [MEDLINE: 9009975] AbrairaC , ColwellJA , NuttallFQ , SawinCT , NagelNJ , ComstockJP , et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18(8):1113‐23. [MEDLINE: 7587846] AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , LevinS , et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care1992;15(11):1560‐71. [MEDLINE: 1308130] AbrairaC , HendersonWG , ColwellJA , NuttallFQ , ComstockJP , EmanueleNV , et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care1998;21(4):574‐9. [MEDLINE: 9571345] AbrairaC , McGuireDK . Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal1999;138(5 Pt 1):S360‐5. [MEDLINE: 10539798] AgrawalL , EmanueleNV , AbrairaC , HendersonWG , LevinSR , SawinCT , et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care1998;21(4):510‐5. [MEDLINE: 9571333] AzadN , EmanueleNV , AbrairaC , HendersonWG , ColwellJ , LevinSR , et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes &amp; its Complications1999;13(5‐6):307‐13. [MEDLINE: 10765007] EmanueleN , AzadN , AbrairaC , HendersonW , ColwellJ , LevinS , et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine1998;158(22):2485‐90. [MEDLINE: 9855387] EmanueleN , KleinR , AbrairaC , ColwellJ , ComstockJ , HendersonWG , et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care1996;19(12):1375‐81. [MEDLINE: 8941467] LevinSR , CoburnJW , AbrairaC , HendersonWG , ColwellJA , EmanueleNV , et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care2000;23(10):1478‐85. [MEDLINE: 11023140] PitaleS , Kernan‐SchroederD , EmanueleN , SawinC , SacksJ , AbrairaC , et al. Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes &amp; its Complications2005;19(4):207‐11. [MEDLINE: 15993354] PitaleSU , AbrairaC , EmanueleNV , McCarrenM , HendersonWG , PacoldI , et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care2000;23(9):1316‐20. [MEDLINE: 10977025] ">VA‐CSDM Study 1992</a>). There was insufficient information to determine sequence generation in the remaining six studies (43%) and these were judged to have unclear risk of bias. </p> </section> <section id="CD010137-sec-0070"> <h5 class="title">Allocation concealment</h5> <p>Seven studies (50%) reported adequate methods for allocation concealment (low risk of bias) (<a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a>; <a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>; <a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a>; <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a>; <a href="./references#CD010137-bbs2-0012" title="Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877‐90. [MEDLINE: 1778353] TurnerR , CullC , HolmanR . United Kingdom Prospective Diabetes Study 17: a 9‐year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non‐insulin‐dependent diabetes mellitus. Annals of Internal Medicine1996;124(1 pt 2):136‐45. [MEDLINE: 8554206] ">UKPDS Study 1991</a>; <a href="./references#CD010137-bbs2-0013" title="AbrairaC , ColwellJ , NuttallF , SawinCT , HendersonW , ComstockJP , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine1997;157(2):181‐8. [MEDLINE: 9009975] AbrairaC , ColwellJA , NuttallFQ , SawinCT , NagelNJ , ComstockJP , et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18(8):1113‐23. [MEDLINE: 7587846] AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , LevinS , et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care1992;15(11):1560‐71. [MEDLINE: 1308130] AbrairaC , HendersonWG , ColwellJA , NuttallFQ , ComstockJP , EmanueleNV , et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care1998;21(4):574‐9. [MEDLINE: 9571345] AbrairaC , McGuireDK . Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal1999;138(5 Pt 1):S360‐5. [MEDLINE: 10539798] AgrawalL , EmanueleNV , AbrairaC , HendersonWG , LevinSR , SawinCT , et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care1998;21(4):510‐5. [MEDLINE: 9571333] AzadN , EmanueleNV , AbrairaC , HendersonWG , ColwellJ , LevinSR , et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes &amp; its Complications1999;13(5‐6):307‐13. [MEDLINE: 10765007] EmanueleN , AzadN , AbrairaC , HendersonW , ColwellJ , LevinS , et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine1998;158(22):2485‐90. [MEDLINE: 9855387] EmanueleN , KleinR , AbrairaC , ColwellJ , ComstockJ , HendersonWG , et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care1996;19(12):1375‐81. [MEDLINE: 8941467] LevinSR , CoburnJW , AbrairaC , HendersonWG , ColwellJA , EmanueleNV , et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care2000;23(10):1478‐85. [MEDLINE: 11023140] PitaleS , Kernan‐SchroederD , EmanueleN , SawinC , SacksJ , AbrairaC , et al. Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes &amp; its Complications2005;19(4):207‐11. [MEDLINE: 15993354] PitaleSU , AbrairaC , EmanueleNV , McCarrenM , HendersonWG , PacoldI , et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care2000;23(9):1316‐20. [MEDLINE: 10977025] ">VA‐CSDM Study 1992</a>; <a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a>). There was insufficient information to determine methods of allocation concealment in the remaining seven studies (50%) and these were judged to have unclear risk of bias. </p> </section> </section> <section id="CD010137-sec-0071"> <h4 class="title">Blinding</h4> <section id="CD010137-sec-0072"> <h5 class="title">Performance bias</h5> <p>Two studies (14%) reported that participants and investigators were masked to treatment (<a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a>; <a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>), three studies (21%) were open‐label and so were considered at high risk of bias (<a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a>; <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a>; <a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a>), and the remaining nine studies (65%) did not provide sufficient information to enable assessment (unclear). </p> </section> <section id="CD010137-sec-0073"> <h5 class="title">Detection bias</h5> <p>Seven studies (50%) reported adequate methods of masking outcome assessment (<a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a>; <a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a>; <a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>; <a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a>; <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a>; <a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a>; <a href="./references#CD010137-bbs2-0013" title="AbrairaC , ColwellJ , NuttallF , SawinCT , HendersonW , ComstockJP , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine1997;157(2):181‐8. [MEDLINE: 9009975] AbrairaC , ColwellJA , NuttallFQ , SawinCT , NagelNJ , ComstockJP , et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18(8):1113‐23. [MEDLINE: 7587846] AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , LevinS , et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care1992;15(11):1560‐71. [MEDLINE: 1308130] AbrairaC , HendersonWG , ColwellJA , NuttallFQ , ComstockJP , EmanueleNV , et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care1998;21(4):574‐9. [MEDLINE: 9571345] AbrairaC , McGuireDK . Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal1999;138(5 Pt 1):S360‐5. [MEDLINE: 10539798] AgrawalL , EmanueleNV , AbrairaC , HendersonWG , LevinSR , SawinCT , et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care1998;21(4):510‐5. [MEDLINE: 9571333] AzadN , EmanueleNV , AbrairaC , HendersonWG , ColwellJ , LevinSR , et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes &amp; its Complications1999;13(5‐6):307‐13. [MEDLINE: 10765007] EmanueleN , AzadN , AbrairaC , HendersonW , ColwellJ , LevinS , et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine1998;158(22):2485‐90. [MEDLINE: 9855387] EmanueleN , KleinR , AbrairaC , ColwellJ , ComstockJ , HendersonWG , et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care1996;19(12):1375‐81. [MEDLINE: 8941467] LevinSR , CoburnJW , AbrairaC , HendersonWG , ColwellJA , EmanueleNV , et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care2000;23(10):1478‐85. [MEDLINE: 11023140] PitaleS , Kernan‐SchroederD , EmanueleN , SawinC , SacksJ , AbrairaC , et al. Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes &amp; its Complications2005;19(4):207‐11. [MEDLINE: 15993354] PitaleSU , AbrairaC , EmanueleNV , McCarrenM , HendersonWG , PacoldI , et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care2000;23(9):1316‐20. [MEDLINE: 10977025] ">VA‐CSDM Study 1992</a>); the remainder did not provide sufficient information and where judged to have unclear risk of bias. </p> </section> </section> <section id="CD010137-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>Nine studies (64%) met criteria for low risk of bias (fewer than 10% missing from follow‐up analyses and balanced numbers across intervention groups with similar reasons for loss to follow‐up) of incomplete outcome data bias (<a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a>; <a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a>; <a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>; <a href="./references#CD010137-bbs2-0006" title="OhkuboY , KishikawaH , ArakiE , MiyataT , IsamiS , MotoyoshiS , et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent diabetes mellitus: a randomized prospective 6‐year study. Diabetes Research &amp; Clinical Practice1995;28(2):103‐17. [MEDLINE: 7587918] ShichiriM , KishikawaH , OhkuboY , WakeN . Long‐term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care2000;23 Suppl 2:B21‐9. [MEDLINE: 10860187] WakeN , HisashigeA , KatayamaT , KishikawaH , OhkuboY , SakaiM , et al. Cost‐effectiveness of intensive insulin therapy for type 2 diabetes: a 10‐year follow‐up of the Kumamoto study. Diabetes Research &amp; Clinical Practice2000;48(3):201‐10. [MEDLINE: 10802159] ">KUMAMOTO Study 1995</a>; <a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a>; <a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a>; <a href="./references#CD010137-bbs2-0011" title="Effect of 6 months of strict metabolic control on eye and kidney function in insulin‐dependent diabetics with background retinopathy. Steno Study Group. Lancet1982;1(8264):121‐4. [MEDLINE: 6119509] ">STENO Study 1982</a>; <a href="./references#CD010137-bbs2-0012" title="Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877‐90. [MEDLINE: 1778353] TurnerR , CullC , HolmanR . United Kingdom Prospective Diabetes Study 17: a 9‐year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non‐insulin‐dependent diabetes mellitus. Annals of Internal Medicine1996;124(1 pt 2):136‐45. [MEDLINE: 8554206] ">UKPDS Study 1991</a>; <a href="./references#CD010137-bbs2-0013" title="AbrairaC , ColwellJ , NuttallF , SawinCT , HendersonW , ComstockJP , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine1997;157(2):181‐8. [MEDLINE: 9009975] AbrairaC , ColwellJA , NuttallFQ , SawinCT , NagelNJ , ComstockJP , et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18(8):1113‐23. [MEDLINE: 7587846] AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , LevinS , et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care1992;15(11):1560‐71. [MEDLINE: 1308130] AbrairaC , HendersonWG , ColwellJA , NuttallFQ , ComstockJP , EmanueleNV , et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care1998;21(4):574‐9. [MEDLINE: 9571345] AbrairaC , McGuireDK . Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal1999;138(5 Pt 1):S360‐5. [MEDLINE: 10539798] AgrawalL , EmanueleNV , AbrairaC , HendersonWG , LevinSR , SawinCT , et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care1998;21(4):510‐5. [MEDLINE: 9571333] AzadN , EmanueleNV , AbrairaC , HendersonWG , ColwellJ , LevinSR , et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes &amp; its Complications1999;13(5‐6):307‐13. [MEDLINE: 10765007] EmanueleN , AzadN , AbrairaC , HendersonW , ColwellJ , LevinS , et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine1998;158(22):2485‐90. [MEDLINE: 9855387] EmanueleN , KleinR , AbrairaC , ColwellJ , ComstockJ , HendersonWG , et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care1996;19(12):1375‐81. [MEDLINE: 8941467] LevinSR , CoburnJW , AbrairaC , HendersonWG , ColwellJA , EmanueleNV , et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care2000;23(10):1478‐85. [MEDLINE: 11023140] PitaleS , Kernan‐SchroederD , EmanueleN , SawinC , SacksJ , AbrairaC , et al. Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes &amp; its Complications2005;19(4):207‐11. [MEDLINE: 15993354] PitaleSU , AbrairaC , EmanueleNV , McCarrenM , HendersonWG , PacoldI , et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care2000;23(9):1316‐20. [MEDLINE: 10977025] ">VA‐CSDM Study 1992</a>), two studies (14%) was at high risk of bias (<a href="./references#CD010137-bbs2-0003" title="CiavarellaA , VanniniP , FlamminiM , BacciL , ForlaniG , BorgninoLC . Effect of long‐term near‐normoglycemia on the progression of diabetic nephropathy. Diabete et Metabolisme1985;11(1):3‐8. [MEDLINE: 3884404] ">Ciavarella 1985</a>; <a href="./references#CD010137-bbs2-0005" title="Feldt‐RasmussenB , MathiesenER , DeckertT . Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin‐dependent diabetes. Lancet1986;2(8519):1300‐4. [MEDLINE: 2878175] Feldt‐RasmussenB , MathiesenER , HegedusL , DeckertT . Kidney function during 12 months of strict metabolic control in insulin‐dependent diabetic patients with incipient nephropathy. New England Journal of Medicine1986;314(11):665‐70. [MEDLINE: 3513009] ">Feldt‐Rasmussen 1986</a>), and the remaining three studies (21%) did not provide sufficient information and were judged to unclear risk of bias. </p> </section> <section id="CD010137-sec-0075"> <h4 class="title">Selective reporting</h4> <p>Eleven studies (89%) reported all expected outcomes and were judged to be at low risk of bias (<a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a>; <a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a>; <a href="./references#CD010137-bbs2-0003" title="CiavarellaA , VanniniP , FlamminiM , BacciL , ForlaniG , BorgninoLC . Effect of long‐term near‐normoglycemia on the progression of diabetic nephropathy. Diabete et Metabolisme1985;11(1):3‐8. [MEDLINE: 3884404] ">Ciavarella 1985</a><a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a>; <a href="./references#CD010137-bbs2-0005" title="Feldt‐RasmussenB , MathiesenER , DeckertT . Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin‐dependent diabetes. Lancet1986;2(8519):1300‐4. [MEDLINE: 2878175] Feldt‐RasmussenB , MathiesenER , HegedusL , DeckertT . Kidney function during 12 months of strict metabolic control in insulin‐dependent diabetic patients with incipient nephropathy. New England Journal of Medicine1986;314(11):665‐70. [MEDLINE: 3513009] ">Feldt‐Rasmussen 1986</a>; <a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a>; <a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a>; <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a>; <a href="./references#CD010137-bbs2-0012" title="Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877‐90. [MEDLINE: 1778353] TurnerR , CullC , HolmanR . United Kingdom Prospective Diabetes Study 17: a 9‐year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non‐insulin‐dependent diabetes mellitus. Annals of Internal Medicine1996;124(1 pt 2):136‐45. [MEDLINE: 8554206] ">UKPDS Study 1991</a>; <a href="./references#CD010137-bbs2-0013" title="AbrairaC , ColwellJ , NuttallF , SawinCT , HendersonW , ComstockJP , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine1997;157(2):181‐8. [MEDLINE: 9009975] AbrairaC , ColwellJA , NuttallFQ , SawinCT , NagelNJ , ComstockJP , et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18(8):1113‐23. [MEDLINE: 7587846] AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , LevinS , et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care1992;15(11):1560‐71. [MEDLINE: 1308130] AbrairaC , HendersonWG , ColwellJA , NuttallFQ , ComstockJP , EmanueleNV , et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care1998;21(4):574‐9. [MEDLINE: 9571345] AbrairaC , McGuireDK . Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal1999;138(5 Pt 1):S360‐5. [MEDLINE: 10539798] AgrawalL , EmanueleNV , AbrairaC , HendersonWG , LevinSR , SawinCT , et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care1998;21(4):510‐5. [MEDLINE: 9571333] AzadN , EmanueleNV , AbrairaC , HendersonWG , ColwellJ , LevinSR , et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes &amp; its Complications1999;13(5‐6):307‐13. [MEDLINE: 10765007] EmanueleN , AzadN , AbrairaC , HendersonW , ColwellJ , LevinS , et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine1998;158(22):2485‐90. [MEDLINE: 9855387] EmanueleN , KleinR , AbrairaC , ColwellJ , ComstockJ , HendersonWG , et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care1996;19(12):1375‐81. [MEDLINE: 8941467] LevinSR , CoburnJW , AbrairaC , HendersonWG , ColwellJA , EmanueleNV , et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care2000;23(10):1478‐85. [MEDLINE: 11023140] PitaleS , Kernan‐SchroederD , EmanueleN , SawinC , SacksJ , AbrairaC , et al. Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes &amp; its Complications2005;19(4):207‐11. [MEDLINE: 15993354] PitaleSU , AbrairaC , EmanueleNV , McCarrenM , HendersonWG , PacoldI , et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care2000;23(9):1316‐20. [MEDLINE: 10977025] ">VA‐CSDM Study 1992</a>; <a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a>). Three studies (21%) were not able to be meta‐analysed and were judged to be at high risk of bias (<a href="./references#CD010137-bbs2-0006" title="OhkuboY , KishikawaH , ArakiE , MiyataT , IsamiS , MotoyoshiS , et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent diabetes mellitus: a randomized prospective 6‐year study. Diabetes Research &amp; Clinical Practice1995;28(2):103‐17. [MEDLINE: 7587918] ShichiriM , KishikawaH , OhkuboY , WakeN . Long‐term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care2000;23 Suppl 2:B21‐9. [MEDLINE: 10860187] WakeN , HisashigeA , KatayamaT , KishikawaH , OhkuboY , SakaiM , et al. Cost‐effectiveness of intensive insulin therapy for type 2 diabetes: a 10‐year follow‐up of the Kumamoto study. Diabetes Research &amp; Clinical Practice2000;48(3):201‐10. [MEDLINE: 10802159] ">KUMAMOTO Study 1995</a>; <a href="./references#CD010137-bbs2-0008" title="Dahl‐JorgensenK , Brinchmann‐HansenO , HanssenKF , GanesT , KierulfP , SmelandE , et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. British Medical Journal Clinical Research Ed1986;293(6556):1195‐9. [MEDLINE: 3096429] Dahl‐JorgensenK , HanssenKF , KierulfP , BjoroT , SandvikL , AagenaesO . Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin‐dependent diabetes mellitus. The Oslo Study. Acta Endocrinologica1988;117(1):19‐25. [MEDLINE: 3289293] ">OSLO Study 1986</a>; <a href="./references#CD010137-bbs2-0011" title="Effect of 6 months of strict metabolic control on eye and kidney function in insulin‐dependent diabetics with background retinopathy. Steno Study Group. Lancet1982;1(8264):121‐4. [MEDLINE: 6119509] ">STENO Study 1982</a>). </p> </section> <section id="CD010137-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>There were three studies (21%) that reported the sponsor was involved in authorship of the study report or in data management or analysis (<a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a>; <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a>; <a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a>). </p> </section> </section> <section id="CD010137-sec-0077"> <h3 class="title" id="CD010137-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD010137-tbl-0001"><b>Summary of findings for the main comparison</b> Tight glycaemic control compared with non‐tight control for preventing diabetic kidney disease (DKD) and its progression</a> </p> <p>The <a href="./full#CD010137-tbl-0001">summary of findings Table for the main comparison</a> for the main comparison provides overall estimates and our confidence in treatment effects for the key (preventing the onset and progression of kidney disease) and safety (cardiovascular events or death) outcomes. </p> <section id="CD010137-sec-0078"> <h4 class="title">Primary outcomes</h4> <section id="CD010137-sec-0079"> <h5 class="title">Doubling of serum creatinine</h5> <p>Tight glycaemic control may make little or no difference to doubling of SCr compared with standard control (<a href="./references#CD010137-fig-0005" title="">Analysis 1.1</a> (4 studies, 26,874 participants): RR 0.84, 95% CI 0.64 to 1.11; I<sup>2</sup>= 73%; low certainty evidence). </p> </section> <section id="CD010137-sec-0080"> <h5 class="title">End‐stage kidney disease</h5> <p>Tight glycaemic control may make little or no difference to patients developing ESKD compared with standard glycaemic control (<a href="./references#CD010137-fig-0006" title="">Analysis 1.2</a> (4 studies, 23,332 participants): RR 0.62, 95% CI 0.34 to 1.12; I<sup>2</sup>= 52%; low certainty evidence). </p> </section> <section id="CD010137-sec-0081"> <h5 class="title">Death (from any cause, cardiovascular causes, or sudden)</h5> <p>Tight glycaemic control probably makes little or no difference to all‐cause mortality (<a href="./references#CD010137-fig-0007" title="">Analysis 1.3</a> (9 studies, 29,094 participants): RR 0.99, 95% CI 0.86 to 1.13; I<sup>2</sup>= 50%; moderate certainty evidence), cardiovascular mortality (<a href="./references#CD010137-fig-0008" title="">Analysis 1.4</a> (6 studies, 23,673 participants): RR 1.19, 95% CI 0.73 to 1.92; I<sup>2</sup>= 85%; low certainty evidence) and sudden death (<a href="./references#CD010137-fig-0009" title="">Analysis 1.5</a> (4 studies, 5913 participants): RR 0.82, 95% CI 0.26 to 2.57; I<sup>2</sup>= 85%; very low certainty evidence) compared with standard glycaemic control. </p> </section> <section id="CD010137-sec-0082"> <h5 class="title">Fatal and non‐fatal cardiovascular events including myocardial infarction and stroke</h5> <p>Tight glycaemic control may make little or no difference to fatal myocardial infarction (<a href="./references#CD010137-fig-0010" title="">Analysis 1.6</a> (3 studies, 14,220 participants): RR 1.11, 95% CI 0.76 to 1.62; I<sup>2</sup>= 24%) and stroke (<a href="./references#CD010137-fig-0011" title="">Analysis 1.7</a> (3 studies, 15,909 participants): RR 1.11, 95% CI 0.71 to 1.75; I<sup>2</sup>= 0%) compared with standard glycaemic control. </p> <p>Tight glycaemic control probably reduces non‐fatal myocardial infarction (<a href="./references#CD010137-fig-0012" title="">Analysis 1.8</a> (5 studies, 25,596 participants): RR 0.82, 95% CI 0.67 to 0.99; I<sup>2</sup>= 46%, moderate certainty evidence), but probably makes little or no difference to the risk of non‐fatal stroke (<a href="./references#CD010137-fig-0013" title="">Analysis 1.9</a> (5 studies, 25,596 participants): RR 0.94, 95% CI 0.68 to 1.31; I<sup>2</sup>= 64%) compared with standard glycaemic control. </p> </section> </section> <section id="CD010137-sec-0083"> <h4 class="title">Secondary outcomes</h4> <section id="CD010137-sec-0084"> <h5 class="title">Onset, progression or regression of microalbuminuria</h5> <p>Tight glycaemic control probably reduces the risk of onset of microalbuminuria compared with standard control (<a href="./references#CD010137-fig-0014" title="">Analysis 1.10</a> (4 studies, 19,846 participants): RR 0.82, 95% CI 0.71 to 0.93; I<sup>2</sup>= 61%, moderate certainty evidence). Similarly, tight glycaemic control probably decreases the risk of progression of microalbuminuria (<a href="./references#CD010137-fig-0015" title="">Analysis 1.11</a> (5 studies, 13,266 participants): RR 0.59, 95% CI 0.38 to 0.93; I<sup>2</sup>= 75%, moderate certainty evidence) compared to standard control. </p> <p><a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a> reported tight glycaemic control may make little or no difference to regression of albuminuria compared with conventional control (<a href="./references#CD010137-fig-0016" title="">Analysis 1.12</a>, (1 study, 73 participants): RR 1.18, 95% CI 0.78 to 1.78). </p> </section> <section id="CD010137-sec-0085"> <h5 class="title">End of treatment urinary albumin‐creatinine ratio</h5> <p>This outcome was not reported in any of the included studies.</p> </section> <section id="CD010137-sec-0086"> <h5 class="title">End of treatment serum creatinine</h5> <p>Tight glycaemic control had may make little of no difference to SCr compared with conventional glycaemic control (<a href="./references#CD010137-fig-0017" title="">Analysis 1.13</a> (4 studies, 12718 participants): MD 0.96 µmol/L, 95% CI ‐0.42 to 2.34; I<sup>2</sup> = 0%). </p> </section> <section id="CD010137-sec-0087"> <h5 class="title">End of treatment creatinine clearance or glomerular filtration rate</h5> <p>Tight glycaemic control may make little of no difference to GFR compared with conventional glycaemic control (<a href="./references#CD010137-fig-0018" title="">Analysis 1.14</a> (3 studies, 164 participants): MD ‐4.86 mL/min, 95% CI ‐15.69 to 5.97; I<sup>2</sup> = 31%). </p> </section> <section id="CD010137-sec-0088"> <h5 class="title">Hypoglycaemia</h5> <p>Data on side effects related to metformin, sulphonylureas, glitazones, meglitinides, alpha‐glucosidase, exenatide, liraglutide and insulin were not reported. The narrative findings for hypoglycaemia are shown in <a href="#CD010137-tbl-0003">Table 2</a> as these were reported in heterogeneous ways that precluded meta‐analysis. </p> <div class="table" id="CD010137-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Narrative table for hypoglycaemia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Control </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Statistical inference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3,1 severe hypoglycaemia /100 patient‐year (830 patient, 16.2%)</p> <p>1 hypoglycaemia‐related death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 severe hypoglycaemia/100 patient‐year (261 patient, 5.1%)</p> <p>1 hypoglycaemia‐related death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7 severe hypoglycaemia/100 patient‐year (150 patients, 2.7%)</p> <p>120 minor hypoglycaemia/100 patient‐year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4 severe hypoglycaemia/100 patient‐year (81 patients, 1.5%)</p> <p>90 minor hypoglycaemia/100 patient‐year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>549 (77%) severe hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165 (23%) severe hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.4% mild hypoglycaemia</p> <p>11.2% moderate hypoglycaemia</p> <p>0% severe hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5% mild hypoglycaemia</p> <p>29% moderate hypoglycaemia</p> <p>6.3% severe hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.52</p> <p>P = 0.001</p> <p>P = 0.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1 serious hypoglycaemia/patient‐year (80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4 serious hypoglycaemia/patient‐year (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 patients ≥1 minor hypoglycaemia</p> <p>5 patients ≥1 major hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 patients ≥1 minor hypoglycaemia</p> <p>12 patients ≥1 major hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.50</p> <p>P = 0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1566 any hypoglycaemia/100 patient‐year</p> <p>12 major hypoglycaemia/100 patient‐year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432 any hypoglycaemia/100 patient‐year</p> <p>4 major hypoglycaemia/100 patient‐year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD010137-sec-0089"> <h5 class="title">End of treatment glycaemic control (HbA1c)</h5> <p>Glycaemic control at the end of treatment was probably reduced with intensive therapy compared with standard therapy (<a href="./references#CD010137-fig-0019" title="">Analysis 1.15</a> (5 studies, 11583 participants): MD ‐1.38%, 95% CI ‐1.93 to ‐0.82; I<sup>2</sup> = 96%). </p> </section> <section id="CD010137-sec-0090"> <h5 class="title">Lipid profile</h5> <p>This outcome was not reported in any of the included studies.</p> </section> </section> <section id="CD010137-sec-0091"> <h4 class="title">Subgroup and sensitivity analysis</h4> <p>Subgroup analysis were run to explore potential different effects of the treatment related to age (greater or less than 60 years old), allocation concealment (unclear versus low risk), study duration (greater or less than 60 months) and GFR (greater or less than 90 mL/min/1.72m<sup>2</sup>). There was no evidence of a difference between the subgroups for any of the outcomes included in the subgroup analysis related to age, allocation concealment, or GFR. </p> <p>We found that in studies with a duration of less than 60 months, the risk of cardiovascular (<a href="./references#CD010137-fig-0022" title="">Analysis 2.3</a>.1: RR 1.73, 95% CI 1.04 to 2.90; test for subgroup differences: Chi<sup>2</sup> = 5.49, (P = 0.02), I<sup>2</sup> = 81.8%) and all‐cause mortality (<a href="./references#CD010137-fig-0026" title="">Analysis 2.7</a>.1: RR 1.18, 95% CI 1.03 to 1.36; test for subgroup differences: Chi<sup>2</sup> = 5.74, (P = 0.02), I<sup>2</sup> = 82.6%) was statistically significant. </p> <p>We did sensitivity analysis excluding <a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a> to check for the robustness of results as this study evaluated a multifactorial intervention including glucose targets but also including cholesterol lowering, lifestyle management, BP control. This did not alter the findings for any outcome, which remained consistent with overall findings with all studies included (specifically for the primary outcomes ESKD: RR 0.66, 95% CI 0.36 to 1.19; all‐cause mortality: RR 1.03, 95% CI 0.93 to 1.14; cardiovascular mortality: RR 1.21, 95% CI 0.71 to 2.07). We did an additional sensitivity analysis restricted to studies involving people with type 2 diabetes. In these sensitivity analyses all treatment effects were not substantively different from the principal analyses including all study populations. </p> <p>We generated a funnel plot for the outcome of all‐cause mortality to assess for evidence of small‐study effects (<a href="#CD010137-fig-0004">Figure 4</a>). There was no evidence of small‐study effects in this meta‐analysis. There were insufficient observations in the meta‐analyses for all other outcomes (fewer than 9 to 10 studies) to permit funnel plot generation. </p> <div class="figure" id="CD010137-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Tight versus non‐tight glycaemic control, outcome: 1.3 All‐cause mortality." data-id="CD010137-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Tight versus non‐tight glycaemic control, outcome: 1.3 All‐cause mortality. </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010137-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010137-sec-0092"></div> <section id="CD010137-sec-0093"> <h3 class="title" id="CD010137-sec-0093">Summary of main results</h3> <p>This review summarises 14 studies involving 29,319 people with diabetes that evaluated the effects of tight versus standard glycaemic control. Studies included people with both type 1 and type 2 diabetes and people with a range of kidney function. Studies lasted approximately five years on average, although this ranged between six months and 10 years. Intensive glycaemic control was achieved by multifactorial behavioural and education interventions in general practice, different insulin regimens, or intensive oral hypoglycaemic medication. </p> <p>Although glucose‐lowering strategies to achieve tighter glucose control led to people experiencing better glycaemic control (reducing their HbA1C by 1.24% on average), this did not result in clinically important reductions in experiences of kidney failure (doubling of SCr or ESKD), or premature mortality or major cardiovascular complications. While treatment might have reduce the risks of non‐fatal myocardial infarction proportionally by 18%, in absolute terms, out of 1,000 people with diabetes receiving interventions to achieve tight glycaemic control for four to eight years might lead to between zero and two people avoiding complications (each of mortality, cardiovascular death, sudden death, ESKD, doubling of SCr, nonfatal myocardial infarction). People who were allocated to tight glycaemic control had measurable reductions in their risk of developing new microalbuminuria or progression to higher levels of microalbuminuria (proportional risk reductions of 18% and 41% respectively), but as these are surrogate measures of kidney injury, these treatment effects are of uncertain future clinical significance for these treated patients. </p> <p>It is possible that tight glycaemic control might have different effects in different practice settings. We therefore examined whether treatment effects were different based on age, duration of treatment, the baseline level of kidney function and the methodological quality of the study. There was no discernible effect of age, kidney function or study methodology on estimated treatment effects. A longer duration of treatment was associated with lower risks of all‐cause mortality and cardiovascular death, although an in‐depth exploration of the mechanisms by which longer treatment might work is beyond the scope of this review and might be confounded by other factors such as study quality or participant characteristics. </p> <p>In general, adverse events were incompletely reports and due to limitations in the evidence because of inconsistent treatment effects measured by different studies, and limitations in studies based on the reporting of methods, the confidence in the evidence for most outcomes was downgraded from high confidence, meaning that future studies might have different results and lead to changing in our knowledge about the impact of glucose control for people with diabetes. </p> <p>Overall, this evidence summary does not support the use of tighter glucose control to offer people with diabetes a lower risk of premature mortality or protection against kidney failure. While tighter glucose control does appear to reduce some biochemical markers of kidney disease, the clinical relevance of these endpoints is uncertain and there is no evidence that these treatment effects translate to a reduction in needing dialysis or kidney transplantation in the long‐term based on the current trial evidence. People may reasonably wish to consider treatment that targets lower blood sugars with the understanding that the potentially harmful consequences of this approach are poorly measured and the absolute clinical treatment benefits are probably small during treatment on average of five to eight years. </p> </section> <section id="CD010137-sec-0094"> <h3 class="title" id="CD010137-sec-0094">Overall completeness and applicability of evidence</h3> <p>Although this review could include studies with a relatively large number of people, there were few studies overall measuring treatment impact on kidney failure and cardiovascular complications. The imprecision in our estimates of treatment effect reduced our confidence in the results, meaning that future studies might provide different results and change our knowledge about the effects of tight glucose control on kidney function. Notably, most of the studies included in this meta‐analysis have involved patients with type 2 diabetes, suggesting the results of this analysis may not be applicable to the management of type 1 diabetes. </p> <p>Although kidney failure requiring dialysis or kidney transplantation is a common complication of diabetes in the long‐term, ESKD was a rare complication for people treated in the included studies, even over treatment lasting 5 to 10 years. Despite over 12,000 people included in available studies, fewer than 2% experienced kidney failure. As kidney failure is a rare outcome, it is very unlikely that future studies will be sufficiently prioritised or statistically large enough to determine whether glycaemic control can prevent long‐term kidney failure. Current studies have measured treatment impact on levels of kidney albumin excretion, a biochemical marker of kidney injury associated with higher risks of kidney failure and cardiovascular complications, however it is unclear whether drug‐related reductions in albuminuria necessarily translate into prevention of kidney failure with treatment. </p> <p>Despite modest average reductions in the risk of nonfatal myocardial infarction for people allocated to tight glycaemic control, the absolute number of people avoiding this complication for 1000 people treated is very small and of uncertain clinical importance. In light of the small absolute benefits of tight glucose control, it is important to have a full understanding of treatment‐related harms. However, existing studies infrequently reported harms, including serious hypoglycaemia, such that people considering treatment to stricter glycaemic targets cannot reasonably balance the advantages and disadvantages of treatment to their health in both the short and long‐term. </p> </section> <section id="CD010137-sec-0095"> <h3 class="title" id="CD010137-sec-0095">Quality of the evidence</h3> <p>We graded our confidence in the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD010137-bbs2-0025" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. [MEDLINE: 21195583] ">Guyatt 2011</a>), which considers study limitations, imprecision, indirectness, inconsistency and publication bias. Overall, most studies had overall unclear risks of bias for most domains of study reporting assessed. Estimated effects on efficacy and safety outcomes were frequently imprecise with confidence intervals that were consistent with both considerable benefit or harm. The drop‐out rate in 10/14 studies was &lt;10%. Moderate heterogeneity in treatment estimates for tight compared with non‐tight glucose control were present in analyses for sudden death, cardiovascular mortality, doubling SCr and onset of microalbuminuria. </p> <p>Overall, based on important limitations, our confidence in the evidence varied between very low and moderate for most outcomes, indicating that future research might have an important impact on the treatment effects observed and may change the estimated treatment impact. We carried out sensitivity analyses to explore the effect of study quality (allocation concealment) in order to assess whether this made any difference to the results. There was no strong evidence that different clinical settings and design modified the results, although the statistical power of these analyses was low and these results are hypothesis‐generating. There was no strong evidence of different treatment effects from smaller studies, though this is difficult to detect with the number of studies in this review. </p> </section> <section id="CD010137-sec-0096"> <h3 class="title" id="CD010137-sec-0096">Potential biases in the review process</h3> <p>We did this review according to a prespecified protocol and using a highly sensitive search strategy without date or language restrictions. We considered the evidence in the context of study methodological limitations using the GRADE approach. We carried out sensitivity analyses to assess the impact of study quality and other participant and study characteristics on the results. </p> <p>Despite these processes, the study has limitations which need to be considered when interpreting the results, principally related to the primary studies in the review. Many of the studies did not report methodological elements in sufficient detail to ascertain risks of bias, which reduced our confidence in the results. The number of people in the studies who reached ESKD was very small, leading to considerable uncertainty for this outcome. Further studies are unlikely to address this issue meaningfully as very large numbers of people will need to be included in studies. As a consequence, many of the studies reported surrogate measures of outcomes for kidney function including albuminuria. While statistical effects were observed, the clinical value of these results remains uncertain. In future, standardised outcomes of most relevance to patients and health professionals will help the design of studies that measure outcomes that are clinically important. </p> </section> <section id="CD010137-sec-0097"> <h3 class="title" id="CD010137-sec-0097">Agreements and disagreements with other studies or reviews</h3> <p>This review finds similar results to a previous similar systematic review of intensive glycaemic control in people with type 2 diabetes and extends analyses of that review to also include kidney function outcomes. As was observed in this review, a previous review did not find any differences in risks of death (due to any cause or cardiovascular‐related) for people treated with tight glycaemic control and there was insufficient information in accrued studies published in 2011 to show conclusive benefits on risks of cardiac complications. When asked, patients foster supportive collaborative relationships to balance their need for support and advice with the need to maintain autonomy and self‐esteem. In this context, this review might help discussions between patients and health practitioners to personalise glycaemic targets to balance the small potential benefits with the uncertain and potentially important hazards of hypoglycaemia (<a href="./references#CD010137-bbs2-0035" title="PatersonBL , ThorneS , DewisM . Adapting to and managing diabetes. Image ‐ the Journal of Nursing Scholarship1998;30(1):57‐62. [MEDLINE: 9549943] ">Paterson 1998</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010137-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD010137-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010137-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010137-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Tight versus non‐tight glycaemic control, outcome: 1.3 All‐cause mortality." data-id="CD010137-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Tight versus non‐tight glycaemic control, outcome: 1.3 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 1 Doubling serum creatinine." data-id="CD010137-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 1 Doubling serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 2 Development ESKD." data-id="CD010137-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 2 Development ESKD.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 3 All‐cause mortality." data-id="CD010137-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 3 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 4 Cardiovascular mortality." data-id="CD010137-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 4 Cardiovascular mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 5 Sudden death." data-id="CD010137-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 5 Sudden death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 6 Fatal myocardial infarction." data-id="CD010137-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 6 Fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 7 Fatal stroke." data-id="CD010137-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 7 Fatal stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 8 Non‐fatal myocardial infarction." data-id="CD010137-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 8 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 9 Non‐fatal stroke." data-id="CD010137-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 9 Non‐fatal stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 10 Onset microalbuminuria." data-id="CD010137-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 10 Onset microalbuminuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 11 Progression of microalbuminuria." data-id="CD010137-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 11 Progression of microalbuminuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 12 Regression of albuminuria." data-id="CD010137-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 12 Regression of albuminuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 13 Serum creatinine." data-id="CD010137-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 13 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 14 Glomerular filtration rate." data-id="CD010137-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 14 Glomerular filtration rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tight versus non‐tight glycaemic control, Outcome 15 HbA1c." data-id="CD010137-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Tight versus non‐tight glycaemic control, Outcome 15 HbA1c.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 1 Cardiovascular mortality (age)." data-id="CD010137-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 1 Cardiovascular mortality (age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 2 Cardiovascular mortality (allocation concealment)." data-id="CD010137-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 2 Cardiovascular mortality (allocation concealment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 3 Cardiovascular mortality (duration of treatment)." data-id="CD010137-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 3 Cardiovascular mortality (duration of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 4 Cardiovascular mortality (GFR)." data-id="CD010137-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 4 Cardiovascular mortality (GFR). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 5 All‐cause mortality (age)." data-id="CD010137-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 5 All‐cause mortality (age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 6 All‐cause mortality (allocation concealment)." data-id="CD010137-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 6 All‐cause mortality (allocation concealment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 7 All‐cause mortality (duration of treatment)." data-id="CD010137-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 7 All‐cause mortality (duration of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 8 All‐cause mortality (GFR)." data-id="CD010137-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 8 All‐cause mortality (GFR). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 9 Non‐fatal myocardial infarction (age)." data-id="CD010137-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 9 Non‐fatal myocardial infarction (age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 10 Non‐fatal myocardial infarction (allocation concealment)." data-id="CD010137-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 10 Non‐fatal myocardial infarction (allocation concealment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 11 Non‐fatal myocardial infarction (duration of treatment)." data-id="CD010137-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 11 Non‐fatal myocardial infarction (duration of treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010137-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/urn:x-wiley:14651858:media:CD010137:CD010137-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_t/tCD010137-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 12 Non‐fatal myocardial infarction (GFR)." data-id="CD010137-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Tight versus non‐tight glycaemic control (subgroup analyses), Outcome 12 Non‐fatal myocardial infarction (GFR). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/media/CDSR/CD010137/image_n/nCD010137-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010137-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tight glycaemic control compared with non‐tight control for preventing diabetic kidney disease (DKD) and its progression</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Tight glycaemic control compared with non‐tight control for preventing DKD and its progression</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with diabetes </p> <p><b>Intervention:</b> tight glycaemic control </p> <p><b>Comparison:</b> non‐tight glycaemic control </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Confidence of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Non‐tight control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Tight control</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Doubling serum creatinine</b> </p> <p>8.3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>39 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>33 per 1000</b> (24.95 to 43.29) </p> <p><b>NNT: 167</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.84</b> (0.64 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26,874 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Imprecision (‐1)</p> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ESKD</b> </p> <p>5.9 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> (1.02 to 3.36) </p> <p><b>NNT: 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> (0.34 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,332 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Imprecision (‐1)</p> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sudden death</b> </p> <p>4.6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> (0.52 to 5.14) </p> <p><b>NNT: 0</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> (0.26 to 2.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5,913 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation (‐1)</p> <p>Imprecision (‐1)</p> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>5.6 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> (13.76‐18.08) </p> <p><b>NNT: 0</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> (0.86 to 1.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29,094 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Imprecision (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>4.4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> (6.57 to 17.28) </p> <p><b>NNH: 500</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> (0.73 to 1.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,673 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Imprecision (‐1)</p> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction</b> </p> <p>5.6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> (5.36 to 7.92) </p> <p><b>NNT: 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.82</b> (0.67 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25,596 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study limitation (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Onset microalbuminuria</b> </p> <p>5.4 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b> (35.42 to 43.24) </p> <p><b>NNT: 143</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> (0.77 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,933 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression of microalbuminuria</b> </p> <p>5.8 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> (1.52 to 3.72) </p> <p><b>NNT: 500</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> (0.38 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,266 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heterogeneity (‐1)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is calculated from data in the meta‐analyses. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence Interval; <b>RR:</b> Risk Ratio; <b>NNT:</b> Number Needed to Treat; <b>NNH:</b> Number Needed to Harm. </p> <p>We did not downgrade for reason of publication bias as insufficient studies contributed to treatment estimates to draw meaningful conclusions </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High confidence:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate confidence:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low confidence:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low confidence:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ESKD ‐ end‐stage kidney disease</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tight glycaemic control compared with non‐tight control for preventing diabetic kidney disease (DKD) and its progression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010137-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of targets definition</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Tight control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b> Non‐tight control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Treatment </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Cut point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Achieved HbA1c (%)*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Treatment </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Cut point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Achieved HbA1c (%)*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intensive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Target HbA1c &lt; 6.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c &lt; 6.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (6.6 to 7.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c: 7.0% to 7.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c: 7.0% to 7.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6 (7 to 8.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intensive with gliclazide ± metformin, thiazolidinediones, acarbose or insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Target HbA1c≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1C ≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.53 ± 0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional with sulphonylurea other than gliclazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c levels defined by local guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local target</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.30 ± 1.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0003" title="CiavarellaA , VanniniP , FlamminiM , BacciL , ForlaniG , BorgninoLC . Effect of long‐term near‐normoglycemia on the progression of diabetic nephropathy. Diabete et Metabolisme1985;11(1):3‐8. [MEDLINE: 3884404] ">Ciavarella 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin infusion (SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 ± 0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2 or 3 daily insulin injections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4 ± 0.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 or more daily insulin injections or insulin infusion (SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prePBG 3.9 to 6.7 mmol/L</p> <p>postPBG &lt; 10 mmol/L</p> <p>HbA1c &lt; 6.05%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prePBG 3.9 to 6.7 mmol/L</p> <p>postPBG &lt; 10 mmol/L</p> <p>HbA1c &lt; 6.05%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 ± NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2 daily insulin injections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No glycosuria, hyperglycaemia and ketonuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No glycosuria hyperglycaemia and ketonuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0005" title="Feldt‐RasmussenB , MathiesenER , DeckertT . Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin‐dependent diabetes. Lancet1986;2(8519):1300‐4. [MEDLINE: 2878175] Feldt‐RasmussenB , MathiesenER , HegedusL , DeckertT . Kidney function during 12 months of strict metabolic control in insulin‐dependent diabetic patients with incipient nephropathy. New England Journal of Medicine1986;314(11):665‐70. [MEDLINE: 3513009] ">Feldt‐Rasmussen 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin infusion (SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FBG levels 5 to 10 mmol/L</p> <p>postPBG morning 4 to 7 mmol/L</p> <p>Avoiding blood glucose levels &lt; 3 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FPG 5 to 10 mmol/L</p> <p>postPBG 4 to 7 mmol/L</p> <p>BG &gt; 3 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 (5.9 to 8.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional insulin therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PostPBG &lt;15 mmol/L</p> <p>Glucose excretion &lt; 20 g/24h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PostPBG &lt; 15 mmol/L</p> <p>Glucose excretion &lt; 20 g/24h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.6 (7.2 to 13.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0006" title="OhkuboY , KishikawaH , ArakiE , MiyataT , IsamiS , MotoyoshiS , et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non‐insulin‐dependent diabetes mellitus: a randomized prospective 6‐year study. Diabetes Research &amp; Clinical Practice1995;28(2):103‐17. [MEDLINE: 7587918] ShichiriM , KishikawaH , OhkuboY , WakeN . Long‐term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care2000;23 Suppl 2:B21‐9. [MEDLINE: 10860187] WakeN , HisashigeA , KatayamaT , KishikawaH , OhkuboY , SakaiM , et al. Cost‐effectiveness of intensive insulin therapy for type 2 diabetes: a 10‐year follow‐up of the Kumamoto study. Diabetes Research &amp; Clinical Practice2000;48(3):201‐10. [MEDLINE: 10802159] ">KUMAMOTO Study 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 or more daily insulin injections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glycaemic control as close to the FBG &lt; 7.78 mmol/L</p> <p>HbA1c &lt; 7.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FBG &lt; 7.78 mmol/L</p> <p>HbA1c &lt; 7.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 ± 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 or 2 daily injections of intermediate‐acting insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>glycaemic control as close to FBG &lt; 7.78 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPG &lt; 7.78 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.4 ± 1.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intensive care + structured education program</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c ≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c ≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 ± 1.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard care by general practitioner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c ≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c ≤ 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 ± 1.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0008" title="Dahl‐JorgensenK , Brinchmann‐HansenO , HanssenKF , GanesT , KierulfP , SmelandE , et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. British Medical Journal Clinical Research Ed1986;293(6556):1195‐9. [MEDLINE: 3096429] Dahl‐JorgensenK , HanssenKF , KierulfP , BjoroT , SandvikL , AagenaesO . Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin‐dependent diabetes mellitus. The Oslo Study. Acta Endocrinologica1988;117(1):19‐25. [MEDLINE: 3289293] ">OSLO Study 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 or more daily insulin injections or insulin infusion (SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 daily mixed insulin injections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intensive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1 ± 0.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5 ± 0.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive multifactorial intervention with behaviour modification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c &lt; 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c &lt; 6.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard care by general practitioner</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c &lt; 7.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c &lt; 7.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0011" title="Effect of 6 months of strict metabolic control on eye and kidney function in insulin‐dependent diabetics with background retinopathy. Steno Study Group. Lancet1982;1(8264):121‐4. [MEDLINE: 6119509] ">STENO Study 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insulin infusion (SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PostPBG &lt; 9 mmol/L</p> <p>No glycosuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PostPBG &lt; 9 mmol/L</p> <p>No glycosuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7 ± 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 or more daily injections of insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PostPBG &lt;15 mmol/L</p> <p>Glucose excretion &lt; 20 g/24h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PostPBG &lt; 15mmol/L</p> <p>Glucose excretion &lt; 20 g/24h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 ± 1.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0012" title="Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug;354(9178):602]. Lancet1998;352(9131):837‐53. [MEDLINE: 9742976] UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia1991;34(12):877‐90. [MEDLINE: 1778353] TurnerR , CullC , HolmanR . United Kingdom Prospective Diabetes Study 17: a 9‐year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non‐insulin‐dependent diabetes mellitus. Annals of Internal Medicine1996;124(1 pt 2):136‐45. [MEDLINE: 8554206] ">UKPDS Study 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive with metformin or sulphonylurea ± metformin or insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPG &lt; 6 mmol/L</p> <p>In insulin‐treated patients, pre‐meal glucose concentrations 4 to 7 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPG &lt; 6 mmol/L</p> <p>prePBG 4 to 7 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (6.2 to 8.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional with diet or metformin ± sulphonylurea or sulphonylurea ± metformin or insulin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maintain FPG &lt; 15 mmol/L</p> <p>without symptoms of hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPG &lt; 15 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9 (6.9 to 8.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0013" title="AbrairaC , ColwellJ , NuttallF , SawinCT , HendersonW , ComstockJP , et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine1997;157(2):181‐8. [MEDLINE: 9009975] AbrairaC , ColwellJA , NuttallFQ , SawinCT , NagelNJ , ComstockJP , et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care1995;18(8):1113‐23. [MEDLINE: 7587846] AbrairaC , EmanueleN , ColwellJ , HendersonW , ComstockJ , LevinS , et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care1992;15(11):1560‐71. [MEDLINE: 1308130] AbrairaC , HendersonWG , ColwellJA , NuttallFQ , ComstockJP , EmanueleNV , et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care1998;21(4):574‐9. [MEDLINE: 9571345] AbrairaC , McGuireDK . Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal1999;138(5 Pt 1):S360‐5. [MEDLINE: 10539798] AgrawalL , EmanueleNV , AbrairaC , HendersonWG , LevinSR , SawinCT , et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care1998;21(4):510‐5. [MEDLINE: 9571333] AzadN , EmanueleNV , AbrairaC , HendersonWG , ColwellJ , LevinSR , et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes &amp; its Complications1999;13(5‐6):307‐13. [MEDLINE: 10765007] EmanueleN , AzadN , AbrairaC , HendersonW , ColwellJ , LevinS , et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine1998;158(22):2485‐90. [MEDLINE: 9855387] EmanueleN , KleinR , AbrairaC , ColwellJ , ComstockJ , HendersonWG , et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care1996;19(12):1375‐81. [MEDLINE: 8941467] LevinSR , CoburnJW , AbrairaC , HendersonWG , ColwellJA , EmanueleNV , et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care2000;23(10):1478‐85. [MEDLINE: 11023140] PitaleS , Kernan‐SchroederD , EmanueleN , SawinC , SacksJ , AbrairaC , et al. Health‐related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes &amp; its Complications2005;19(4):207‐11. [MEDLINE: 15993354] PitaleSU , AbrairaC , EmanueleNV , McCarrenM , HendersonWG , PacoldI , et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care2000;23(9):1316‐20. [MEDLINE: 10977025] ">VA‐CSDM Study 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intensive therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c as close to the normal range as possible (5.1 ± 1% (mean ± 2 SD))</p> <p>Normal mean FSG 4.44 to 6.38 mmol/L</p> <p>Other prePBG &lt; 7.22 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1c 5.1% + 1</p> <p>FBG 4.44 to 6.38 mmol/L</p> <p>prePBG &lt; 7.22 mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1 ± 0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conventional therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avoid diabetic symptoms, excessive glycosuria, or overt hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No diabetes, glycosuria or hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1 ± NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intensive with maximal OHA doses ± insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aiming for HbA1c ≤ 6%</p> <p>A priority is to avoid hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c ≤ 6.0%</p> <p>No hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9 (NR)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional with half the maximal OHA doses ± insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Avoidance of deterioration of HbA1c 8% to 9% and preventing symptoms of glycosuria, hypoglycaemia, and ketonuria </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HbA1c 8% to 9%</p> <p>No glycosuria, hyperglycaemia and ketonuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 (NR)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>*</b> value reported as mean ± SD or median (range) </p> <p>FBG ‐ fasting blood glucose; HbA1c ‐ glycated haemoglobin; NR: not reported; PBG ‐ prandial blood glucose; SC‐ subcutaneous </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of targets definition</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010137-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Narrative table for hypoglycaemia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Control </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Statistical inference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0001" title="ACCORD Study Group, ACCORD Eye Study Group, ChewEY , AmbrosiusWT , DavisMD , DanisRP , et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine2010;363(3):233‐44. [MEDLINE: 20587587] ACCORD Study Group, BuseJB , BiggerJT , ByingtonRP , CooperLS , CushmanWC , et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology2007;99(12A):21i‐33i. [MEDLINE: 17599422] ACCORD Study Group, CushmanWC , EvansGW , ByingtonRP , GoffDCJr , GrimmRHJr , et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine2010;362(17):1575‐85. [MEDLINE: 20228401] ACCORD Study Group, GersteinHC , MillerME , GenuthS , Ismail‐BeigiF , BuseJB , et al. Long‐term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine2011;364(9):818‐28. [MEDLINE: 21366473] ACCORD Study Group, GinsbergHN , ElamMB , LovatoLC , CrouseJR3rd , LeiterLA , et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine2010;362(17):1563‐74. [MEDLINE: 20228404] Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC , MillerME , ByingtonRP , GoffDCJr , BiggerJT , et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine2008;358(24):2545‐59. [MEDLINE: 18539917] BarzilayJI , HowardAG , EvansGW , FlegJL , CohenRM , BoothGL , et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care2012;35(7):1401‐5. [MEDLINE: 22723577] BarzilayJI , LovatoJF , MurrayAM , WilliamsonJ , Ismail‐BeigiF , KarlD , et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN2013;8(11):1907‐14. [MEDLINE: 23990163] BondsDE , CravenTE , BuseJ , CrouseJR , CuddihyR , ElamM , et al. Fenofibrate‐associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia2012;55(6):1641‐50. [MEDLINE: 22450889] BondsDE , KurashigeEM , BergenstalR , BrillonD , DomanskiM , FelicettaJV , et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):80i‐9i. [MEDLINE: 17599428] BondsDE , MillerME , BergenstalRM , BuseJB , ByingtonRP , CutlerJA , et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ2010;340:b4909. [MEDLINE: 20061358] BondsDE , MillerME , DudlJ , FeinglosM , Ismail‐BeigiF , MalozowskiS , et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders2012;12:5. [MEDLINE: 22646230] ChewEY , AmbrosiusWT , HowardLT , GrevenCM , JohnsonS , DanisRP , et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD‐EYE). American Journal of Cardiology2007;99(12A):103i‐11i. [MEDLINE: 17599420] CushmanWC , GrimmRHJr , CutlerJA , EvansGW , CapesS , CorsonMA , et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):44i‐55i. [MEDLINE: 17599425] FatemiO , YuriditskyE , TsioufisC , TsachrisD , MorganT , BasileJ , et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology2014;114(8):1217‐22. [MEDLINE: 25159234] FonsecaV , McDuffieR , CallesJ , CohenRM , FeeneyP , FeinglosM , et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care2013;36(8):2162‐8. [MEDLINE: 23412077] GenuthS , Ismail‐BeigiF . Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology &amp; Metabolism2012;97(1):41‐8. [MEDLINE: 22049171] GersteinHC , AmbrosiusWT , DanisR , Ismail‐BeigiF , CushmanW , CallesJ , et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care2013;36(5):1266‐71. [MEDLINE: 23238658] GersteinHC , MillerME , Ismail‐BeigiF , LargayJ , McDonaldC , LochnanHA , et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet2014;384(9958):1936‐41. [MEDLINE: 25088437] GersteinHC , RiddleMC , KendallDM , CohenRM , GolandR , FeinglosMN , et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):34i‐43i. [MEDLINE: 17599423] GinsbergHN , BondsDE , LovatoLC , CrouseJR , ElamMB , LinzPE , et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):56i‐67i. [MEDLINE: 17599426] GoffDCJr , GersteinHC , GinsbergHN , CushmanWC , MargolisKL , ByingtonRP , et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):4i‐20i. [MEDLINE: 17599424] IsakovaT , CravenTE , SciallaJJ , NickolasTL , SchnallA , BarzilayJ , et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone2015;78:23‐7. [MEDLINE: 25937184] Ismail‐BeigiF , CravenT , BanerjiMA , BasileJ , CallesJ , CohenRM , et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet2010;376(9739):419‐30. [MEDLINE: 20594588] Ismail‐BeigiF , CravenTE , O'ConnorPJ , KarlD , Calles‐EscandonJ , HramiakI , et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International2012;81(6):586‐94. [MEDLINE: 22166848] KingryC , BastienA , BoothG , GeraciTS , KirpachBR , LovatoLC , et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology2007;99(12A):68i‐79i. [MEDLINE: 17599427] LinzPE , LovatoLC , ByingtonRP , O'ConnorPJ , LeiterLA , WeissD , et al. Paradoxical reduction in HDL‐C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care2014;37(3):686‐93. [MEDLINE: 24296848] MargolisKL , O'ConnorPJ , MorganTM , BuseJB , CohenRM , CushmanWC , et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care2014;37(6):1721‐8. [MEDLINE: 24595629] MeierM , HummelM . Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence‐based strategies. Vascular Health &amp; Risk Management2009;5:859‐71. [MEDLINE: 19898642] MillerME , BondsDE , GersteinHC , SeaquistER , BergenstalRM , Calles‐EscandonJ , et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ2010;340:b5444. [MEDLINE: 20061360] MillerME , WilliamsonJD , GersteinHC , ByingtonRP , CushmanWC , GinsbergHN , et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care2014;37(3):634‐43. [MEDLINE: 24170759] MottlAK , PajewskiN , FonsecaV , Ismail‐BeigiF , ChewE , AmbrosiusWT , et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes &amp; its Complications2014;28(6):874‐9. [MEDLINE: 25123755] MychaleckyjJC , CravenT , NayakU , BuseJ , CrouseJR , ElamM , et al. Reversibility of fenofibrate therapy‐induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care2012;35(5):1008‐14. [MEDLINE: 22432114] MychaleckyjJC , FarberEA , ChmielewskiJ , ArtaleJ , LightLS , BowdenDW , et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome‐wide genetic tests after long term storage. Journal of Translational Medicine2011;9:91. [MEDLINE: 21663644] NadkarniGN , RaoV , Ismail‐BeigiF , FonsecaVA , ShahSV , SimonsonMS , et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN2016;11(8):1343‐52. [MEDLINE: 27189318] PapademetriouV , LovatoL , DoumasM , NylenE , MottlA , CohenRM , et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International2015;87(3):649‐59. [MEDLINE: 25229335] Pop‐BusuiR , EvansGW , GersteinHC , FonsecaV , FlegJL , HoogwerfBJ , et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care2010;33(7):1578‐84. [MEDLINE: 20215456] PunthakeeZ , MillerME , LaunerLJ , WilliamsonJD , LazarRM , Cukierman‐YaffeeT , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care2012;35(4):787‐93. [MEDLINE: 22374637] RaischDW , FeeneyP , GoffDCJr , NarayanKM , O'ConnorPJ , ZhangP , et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology2012;11:35. [MEDLINE: 22515638] Reyes‐SofferG , NgaiCI , LovatoL , KarmallyW , RamakrishnanR , HolleranS , et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care2013;36(2):422‐8. [MEDLINE: 23033246] RiddleMC , AmbrosiusWT , BrillonDJ , BuseJB , ByingtonRP , CohenRM , et al. Epidemiologic relationships between A1C and all‐cause mortality during a median 3.4‐year follow‐up of glycemic treatment in the ACCORD trial. Diabetes Care2010;33(5):983‐90. [MEDLINE: 20427682] SamaropoulosXF , LightL , AmbrosiusWT , MarcovinaSM , ProbstfieldJ , JrDC . The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research &amp; Clinical Practice2012;95(3):389‐98. [MEDLINE: 22019270] SeaquistER , MillerME , BondsDE , FeinglosM , GoffDCJr , PetersonK , et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care2012;35(2):409‐14. [MEDLINE: 22179956] StrylewiczG , DoctorJ . Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials2010;7(4):380‐9. [MEDLINE: 20571135] SullivanMD , AndersonRT , AronD , AtkinsonHH , BastienA , ChenGJ , et al. Health‐related quality of life and cost‐effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology2007;99(12A):90i‐102i. [MEDLINE: 17599429] SullivanMD , O'ConnorP , FeeneyP , HireD , SimmonsDL , RaischDW , et al. Depression predicts all‐cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care2012;35(8):1708‐15. [MEDLINE: 22619083] ThethiT , RajapurkarM , WalkerP , McDuffieR , GoffDCJr , ProbstfieldJ , et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria‐‐a substudy of the ACCORD Trial. Clinical Chemistry2011;57(2):341‐4. [MEDLINE: 21159897] WilliamsonJD , LaunerLJ , BryanRN , CokerLH , LazarRM , GersteinHC , et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine2014;174(3):324‐33. [MEDLINE: 24493100] WilliamsonJD , MillerME , BryanRN , LazarRM , CokerLH , JohnsonJ , et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD‐MIND): rationale, design, and methods. American Journal of Cardiology2007;99(12A):112i‐22i. [MEDLINE: 17599421] ">ACCORD Study 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3,1 severe hypoglycaemia /100 patient‐year (830 patient, 16.2%)</p> <p>1 hypoglycaemia‐related death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 severe hypoglycaemia/100 patient‐year (261 patient, 5.1%)</p> <p>1 hypoglycaemia‐related death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0002" title="Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified‐release controlled evaluation. Journal of Hypertension ‐ Supplement2001;19(4):S21‐8. [MEDLINE: 11848259] ADVANCE Collaborative Group. ADVANCE‐‐Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine2005;22(7):882‐8. [MEDLINE: 15975103] ADVANCE Collaborative Group, PatelA , MacMahonS , ChalmersJ , NealB , BillotL , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2008;358(24):2560‐72. [MEDLINE: 18539916] ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease‐‐Preterax and Diamicron MR Controlled Evaluation. Diabetologia2001;44(9):1118‐20. [MEDLINE: 11596665] BlomsterJI , WoodwardM , ZoungasS , HillisGS , HarrapS , NealB , et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open2016;6(1):e009668. [MEDLINE: 26747037] ChalmersJ . ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs2003;63(Spec No 1):39‐44. [MEDLINE: 12708881] ChalmersJ , MarreM , deGalanBE , ZoungasS , HametP , NealB , et al. The efficacy of lowering HbAlc with a gliclazide modified release‐based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia2009;52(Suppl 1):S354. [EMBASE: 70068392] ChalmersJ , PerkovicV , JoshiR , PatelA . ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension ‐ Supplement2006;24(5):S22‐S8. [MEDLINE: 16936533] CooperME , ZoungasS , JardineM , HataJ , PerkovicV , NinomiyaT , et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia2011;54(1 Suppl):S442. [EMBASE: 70563236] HataJ , ArimaH , RothwellPM , WoodwardM , ZoungasS , AndersonC , et al. Effects of visit‐to‐visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation2013;128(12):1325‐34. [MEDLINE: 23926207] HeerspinkHJ , NinomiyaT , PerkovicV , WoodwardM , ZoungasS , CassA , et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal2010;31(23):2888‐96. [MEDLINE: 20501479] JardineM , NinomiyaT , PerkovicV , WoodwardM , PillaiA , CassA , et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F‐PO1916]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):543A. [CENTRAL: CN‐00724903] JardineMJ , HataJ , WoodwardM , PerkovicV , NinomiyaT , ArimaH , et al. Prediction of kidney‐related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases2012;60(5):770‐8. [MEDLINE: 22694950] MohammediK , WoodwardM , HirakawaY , ZoungasS , ColagiuriS , HametP , et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE‐ON study. Cardiovascular Diabetology2016;15(1):129. [MEDLINE: 27590190] NinomiyaT , ZoungasS , NealB , WoodwardM , PatelA , PerkovicV , et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension2010;28(6):1141‐9. [MEDLINE: 20486273] PatelA , ADVANCE Collaborative Group, MacMahonS , ChalmersJ , NealB , WoodwardM , et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet2007;370(9590):829‐40. [MEDLINE: 17765963] PatelA , ChalmersJ , PoulterN . ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension2005;19 Suppl 1:S27‐32. [MEDLINE: 16075030] PerkovicV , HeerspinkHL , ChalmersJ , WoodwardM , JunM , LiQ , et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International2013;83(3):517‐23. [MEDLINE: 23302714] PerkovicV , NinomiyaT , deGalanBE , ZoungasS , CassA , PatelA , et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB‐002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4‐9; Philadelphia, PA. 2008. [CENTRAL: CN‐00740604] PerkovicV , ZoungasS , HeerspinkHL , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease ‐ new data from the ADVANCE trial [abstract no: 071]. Nephrology2011;16(Suppl 1):42. [EMBASE: 70532419] PerkovicV , deGalanB , ChalmersJ , NinomiyaT , PatelA , CassA , et al. Renoprotection with perindopril‐indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology2008;13(Suppl 3):A121. [CENTRAL: CN‐00740462] PoulterNR . Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension ‐ Supplement2009;27(1):S3‐8. [MEDLINE: 19483505] WongG , ZoungasS , LoS , ChalmersJ , CassA , NealB , et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation2012;27(8):3337‐44. [MEDLINE: 22357699] WongMG , PerkovicV , ChalmersJ , WoodwardM , LiQ , CooperME , et al. Long‐term benefits of intensive glucose control for preventing end‐stage kidney disease: ADVANCE‐ON. Diabetes Care2016;39(5):694‐700. [MEDLINE: 27006512] ZoungasS , ChalmersJ , NinomiyaT , LiQ , CooperME , ColagiuriS , et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia2012;55(3):636‐43. [MEDLINE: 22186981] ZoungasS , Lambers HeerspinkHJ , ChalmersJ , WoodwardM , JunM , CassA , et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia2011;54(1 Suppl):S23. [EMBASE: 70562184] ZoungasS , PatelA , ChalmersJ , deGalanBE , LiQ , BillotL , et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine2010;363(15):1410‐8. [MEDLINE: 20925543] ZoungasS , PerkovicV , NinomiyaT , deGalanBE , PillaiI , PatelA , et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension2009;53(6):1103. [EMBASE: 70036220] ZoungasS , deGalanBE , NinomiyaT , GrobbeeD , HametP , HellerS , et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care2009;32(11):2068‐74. [MEDLINE: 19651921] deGalanBE , NinomiyaT , PerrovicV , PillaiA , PatelA , NealACB , et al. Renoprotective effects of blood pressure lowering with perindopril‐indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes2008;57(Suppl 1):A218‐9. [CENTRAL: CN‐00757885] deGalanBE , PerkovicV , NinomiyaT , PillaiA , PatelA , CassA , et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology2009;20(4):883‐92. [MEDLINE: 19225038] ">ADVANCE Study 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7 severe hypoglycaemia/100 patient‐year (150 patients, 2.7%)</p> <p>120 minor hypoglycaemia/100 patient‐year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4 severe hypoglycaemia/100 patient‐year (81 patients, 1.5%)</p> <p>90 minor hypoglycaemia/100 patient‐year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0004" title="Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes1986;35(5):530‐45. [MEDLINE: 2869996] Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care1990;13(4):427‐33. [MEDLINE: 2180661] Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care1987;10(1):1‐19. [MEDLINE: 2882967] Effect of intensive diabetes treatment on the development and progression of long‐term complications in adolescents with insulin‐dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics1994;125(2):177‐88. [MEDLINE: 8040759] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International1995;47(6):1703‐20. [MEDLINE: 7643540] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine2000;342(6):381‐9. [MEDLINE: 10666428] The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine1993;329(14):977‐86. [MEDLINE: 8366922] Al‐KatebH , BorightAP , MireaL , XieX , SutradharR , MowjoodiA , et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes2008;57(1):218‐28. [MEDLINE: 17914031] DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long‐term follow‐up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes &amp; Endocrinology2014;2(10):793‐800. [MEDLINE: 25043685] DCCT/EDIC Research Group, AielloLP , SunW , DasA , GangaputraS , KissS , et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine2015;372(18):1722‐33. [MEDLINE: 25923552] DCCT/EDIC Research Group, deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine2011;365(25):2366‐76. [MEDLINE: 22077236] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, NathanDM , ZinmanB , ClearyPA , BacklundJY , GenuthS , et al. Modern‐day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983‐2005). Archives of Internal Medicine2009;169(14):1307‐16. [MEDLINE: 19636033] GaiN , TurkbeyEB , NazarianS , van derGeestRJ , LiuCY , LimaJA , et al. T1 mapping of the gadolinium‐enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine2011;65(5):1407‐15. [MEDLINE: 21500267] Gubitosi‐KlugRA , DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care2014;37(1):44‐9. [MEDLINE: 24356597] HoeldtkeRD , HampeCS , BekrisLM , HobbsG , BrynerKD , LernmarkA , et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology2007;185(1‐2):182‐9. [MEDLINE: 17328966] JacobsonAM , BraffettBH , ClearyPA , Gubitosi‐KlugRA , LarkinME , DCCT/EDIC Research Group. The long‐term effects of type 1 diabetes treatment and complications on health‐related quality of life: a 23‐year follow‐up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care2013;36(10):3131‐8. [MEDLINE: 23835693] JenkinsAJ , YuJ , AlaupovicP , BasuA , KleinRL , Lopes‐VirellaM , et al. Apolipoprotein‐defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes &amp; its Complications2013;27(5):447‐53. [MEDLINE: 23850262] KilpatrickES , RigbyAS , AtkinSL . A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care2008;31(11):2198‐202. [MEDLINE: 18650371] KimC , ClearyPA , CowieCC , BraffettBH , DunnRL , LarkinME , et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care2014;37(3):701‐8. [MEDLINE: 24170751] KleinRL , HammadSM , BakerNL , HuntKJ , Al GadbanMM , ClearyPA , et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical &amp; Experimental2014;63(10):1287‐95. [MEDLINE: 25088746] KramerCK , RetnakaranR . Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine2013;30(11):1333‐41. [MEDLINE: 23909911] LachinJM , McGeeP , PalmerJP , DCCT/EDIC Research Group. Impact of C‐peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes2014;63(2):739‐48. [MEDLINE: 24089509] LarkinME , BacklundJY , ClearyP , BaylessM , SchaeferB , CanadyJ , et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine2010;27(4):451‐8. [MEDLINE: 20536518] LeeCC , SharpSJ , WexlerDJ , AdlerAI . Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care2010;33(7):1454‐6. [MEDLINE: 20357378] LeveyAS , GreeneT , SchluchterMD , ClearyPA , TeschanPE , LorenzRA , et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology1993;4(5):1159‐71. [MEDLINE: 8305642] LinJ , MansonJ , SchaumbergD . Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F‐PO1015]. Journal of the American Society of Nephrology2007;18(Abstracts):325A‐6A. Lopes‐VirellaMF , BakerNL , HuntKJ , ClearyPA , KleinR , VirellaG , et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care2013;36(8):2317‐23. [MEDLINE: 23514730] Lopes‐VirellaMF , CarterRE , BakerNL , LachinJ , VirellaG , DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation2012;27(4):1416‐23. [MEDLINE: 21856760] McGeeP , SteffesM , NowickiM , BaylessM , Gubitosi‐KlugR , ClearyP , et al. Insulin secretion measured by stimulated C‐peptide in long‐established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine2014;31(10):1264‐8. [MEDLINE: 24836354] MolitchME , SteffesM , SunW , RutledgeB , ClearyP , deBoerIH , et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care2010;33(7):1536‐43. [MEDLINE: 20413518] NathanDM , SteffesMW , SunW , RyndersGP , LachinJM . Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry2011;57(2):286‐90. [MEDLINE: 21030684] PolakJF , BacklundJY , ClearyPA , HarringtonAP , O'LearyDH , LachinJM , et al. Progression of carotid artery intima‐media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes2011;60(2):607‐13. [MEDLINE: 21270271] SiebertC , ClarkCMJr . Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials1993;14(1):30‐44. [MEDLINE: 8440093] TelloA , MondressM , FanY , ThomasW , SteffesM , IbrahimH . The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU‐PO169]. Journal of the American Society of Nephrology2004;15(Oct):569A. [CENTRAL: CN‐00583257] TurkbeyEB , BacklundJY , GenuthS , JainA , MiaoC , ClearyPA , et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation2011;124(16):1737‐46. [MEDLINE: 21947298] WhiteNH , SunW , ClearyPA , DanisRP , DavisMD , HainsworthDP , et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology2008;126(12):1707‐15. [MEDLINE: 19064853] WhiteNH , SunW , ClearyPA , TamborlaneWV , DanisRP , HainsworthDP , et al. Effect of prior intensive therapy in type 1 diabetes on 10‐year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes2010;59(5):1244‐53. [MEDLINE: 20150283] YounesN , ClearyPA , SteffesMW , deBoerIH , MolitchME , RutledgeBN , et al. Comparison of urinary albumin‐creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN2010;5(7):1235‐42. [MEDLINE: 20448066] deBoerIH , AfkarianM , RueTC , ClearyPA , LachinJM , MolitchME , et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology2014;25(10):2342‐50. [MEDLINE: 24925722] deBoerIH , RueTC , ClearyPA , LachinJM , MolitchME , SteffesMW , et al. Long‐term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine2011;171(5):412‐20. [MEDLINE: 21403038] deBoerIH , SunW , ClearyPA , LachinJM , MolitchME , SteffesM , et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB‐OR05]. Journal of the American Society of Nephrology2011;22(Abstracts):2B. ">DCCT 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>549 (77%) severe hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165 (23%) severe hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010137-bbs2-0007" title="CrastoW , JarvisJ , KhuntiK , SkinnerTC , GrayLJ , BrelaJ , et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research &amp; Clinical Practice2011;93(3):328‐36. [MEDLINE: 21640424] CrastoW , KhuntiK , JarvisKJ , SkinnerTC , GrayLJ , BrelaJ , et al. Impact of intensive multi‐factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine2011;28(Suppl 1):166. [EMBASE: 70631246] CrastoWA , JarvisJ , BrelaJ , DalyH , GrayLJ , TroughtonJ , et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine2009;26(Suppl 1):160. [EMBASE: 70342536] ">MEMO Study 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.4% mild hypoglycaemia</p> <p>11.2% moderate hypoglycaemia</p> <p>0% severe hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5% mild hypoglycaemia</p> <p>29% moderate hypoglycaemia</p> <p>6.3% severe hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P = 0.52</p> <p>P = 0.001</p> <p>P = 0.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0009" title="Jensen‐UrstadK , ReichardP , Jensen‐UrstadM . Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine1999;245(1):57‐61. [MEDLINE: 10095817] JohanssonJ , ReichardP , Jensen‐UrstadK , RosforsS , Jensen‐UrstadM . Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima‐media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation2003;33(6):472‐9. [MEDLINE: 12795643] RathsmanB , Jensen‐UrstadK , NystromT . Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long‐term follow‐up study. Diabetologia2014;57(8):1703‐10. [MEDLINE: 24802206] ReichardP . Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research &amp; Clinical Practice1992;16(2):151‐6. [MEDLINE: 1600854] ReichardP , BerglundB , BritzA , CarsI , NilssonBY , RosenqvistU . Intensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine1991;230(2):101‐8. [MEDLINE: 1865159] ReichardP , BritzA , CarlssonP , CarsI , LindbladL , NilssonBY , et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine1990;228(5):511‐7. [MEDLINE: 2254723] ReichardP , BritzA , CarsI , NilssonBY , Sobocinsky‐OlssonB , RosenqvistU . The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica1988;224(2):115‐22. [MEDLINE: 3048052] ReichardP , Jensen‐UrstadK , EricssonM , Jensen‐UrstadM , LindbladLE . Autonomic neuropathy‐‐a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine2000;17(12):860‐6. [MEDLINE: 11168329] ReichardP , NilssonBY , RosenqvistU . The effect of long‐term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine1993;329(5):304‐9. [MEDLINE: 8147960] ReichardP , PihlM . Mortality and treatment side‐effects during long‐term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes1994;43(2):313‐7. [MEDLINE: 8288056] ReichardP , PihlM , RosenqvistU , SuleJ . Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia1996;39(12):1483‐8. [MEDLINE: 8960830] ReichardP , RosenqvistU . Nephropathy is delayed by intensified insulin treatment in patients with insulin‐dependent diabetes mellitus and retinopathy. Journal of Internal Medicine1989;226(2):81‐7. [MEDLINE: 2671247] ReichardP , ToomingasB , RosenqvistU . Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator1994;20(6):503‐8. [MEDLINE: 7851263] ">SDIS Study 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1 serious hypoglycaemia/patient‐year (80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4 serious hypoglycaemia/patient‐year (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0010" title="GaedeP , Lund‐AndersenH , ParvingHH , PedersenO . Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine2008;358(6):580‐91. [MEDLINE: 18256393] GaedeP , ParvingH , PedersenO . Multifactorial intervention in patients with type 2 diabetes: long‐term effects on mortality and vascular complications [abstract no: SA‐FC042]. Journal of the American Society of Nephrology2007;18(Abstracts):43A. [CENTRAL: CN‐00740461] GaedeP , ValentineWJ , PalmerAJ , TuckerDM , LammertM , ParvingHH , et al. Cost‐effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno‐2 study. Diabetes Care2008;31(8):1510‐5. [MEDLINE: 18443195] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The STENO‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F‐FC031]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):72a. [CENTRAL: CN‐00445410] GaedeP , VedelP , LarsenN , JensenG , ParvingHH , PedersenO . The Steno‐2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1‐5; Budapest, Hungary. 2002. GaedeP , VedelP , LarsenN , JensenGV , ParvingHH , PedersenO . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine2003;348(5):383‐93. [MEDLINE: 12556541] GaedeP , VedelP , ObelJ , ParvingHH , PedersenO . Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology1996;7(9):1357. [CENTRAL: CN‐00445411] GaedeP , VedelP , ParvingHH , PedersenO . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet1999;353(9153):617‐22. [MEDLINE: 10030326] GaedePH , JepsenPV , ParvingHH , PedersenOB . Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno‐2 study [Intensiveret multifaktoriel intervention hos patienter med type 2‐diabetes mellitus og mikroalbuminuri: Steno‐2‐studiet]. Ugeskrift for Laeger1999;161(30):4277‐85. [MEDLINE: 10439688] ">STENO‐2 Study 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 patients ≥1 minor hypoglycaemia</p> <p>5 patients ≥1 major hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 patients ≥1 minor hypoglycaemia</p> <p>12 patients ≥1 major hypoglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.50</p> <p>P = 0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010137-bbs2-0014" title="AbrairaC , DuckworthW , McCarrenM , EmanueleN , ArcaD , RedaD , et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2003;17(6):314‐22. [MEDLINE: 14583175] AbrairaC , DuckworthWC , MoritzT , VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity &amp; Metabolism2009;11(2):150‐6. [MEDLINE: 18671796] AgrawalL , AzadN , EmanueleNV , BahnGD , KaufmanDG , MoritzTE , et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(9):2090‐4. [MEDLINE: 21775749] AleleJD , LuttrellLM , HollisBW , LuttrellDK , HuntKJ , VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis2013;228(2):502‐7. [MEDLINE: 23608249] AndersonRJ , BahnGD , EmanueleNV , MarksJB , DuckworthWC , VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(10):2782‐8. [MEDLINE: 25048382] AndersonRJ , BahnGD , MoritzTE , KaufmanD , AbrairaC , DuckworthW , et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care2011;34(1):34‐8. [MEDLINE: 21059830] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , McCarrenM , et al. Association of PAI‐1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2014;37(2):501‐6. [MEDLINE: 24101699] AzadN , AgrawalL , EmanueleNV , KleinR , BahnGD , ReavenP , et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia2014;57(6):1124‐31. [MEDLINE: 24599110] AzarM , LyonsTJ , AlaupovicP , StonerJA , QuirogaC , KaufmanDG , et al. Apolipoprotein‐defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes &amp; its Complications2013;27(6):627‐32. [MEDLINE: 23911536] DuckworthW , AbrairaC , MoritzT , RedaD , EmanueleN , ReavenP , et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024‐5; PMID: 19726779]. New England Journal of Medicine2009;360(2):129‐39. [MEDLINE: 19092145] DuckworthWC , AbrairaC , MoritzTE , DavisSN , EmanueleN , GoldmanS , et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes &amp; its Complications2011;25(6):355‐61. [MEDLINE: 22055259] DuckworthWC , McCarrenM , AbrairaC , VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care2001;24(5):942‐5. [MEDLINE: 11347758] DuckworthWC , McCarrenM , AbrairaC , VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice2006;12 Suppl 1:85‐8. [MEDLINE: 16627388] EmanueleN , KleinR , MoritzT , DavisMD , GlanderK , AndersonR , et al. Comparison of dilated fundus examinations with seven‐field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes &amp; its Complications2009;23(5):323‐9. [MEDLINE: 18406632] EmanueleN , MoritzT , KleinR , DavisMD , GlanderK , KhannaA , et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research &amp; Clinical Practice2009;86(2):104‐10. [MEDLINE: 19720420] EmanueleN , SacksJ , KleinR , RedaD , AndersonR , DuckworthW , et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care2005;28(8):1954‐8. [MEDLINE: 16043738] HaywardRA , ReavenPD , WiitalaWL , BahnGD , RedaDJ , GeL , et al. Follow‐up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine2015;372(23):2197‐206. [MEDLINE: 26039600] JenkinsAJ , FuD , AzarM , StonerJA , KaufmanDG , ZhangS , et al. Clinical correlates of serum pigment epithelium‐derived factor in type 2 diabetes patients. Journal of Diabetes &amp; its Complications2014;28(3):353‐9. [MEDLINE: 24560422] KirkmanMS , McCarrenM , ShahJ , DuckworthW , AbrairaC , VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes &amp; its Complications2006;20(2):75‐80. [MEDLINE: 16504835] KoskaJ , SaremiA , BahnG , YamashitaS , ReavenPD , Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2013;36(8):2408‐14. [MEDLINE: 23536583] Lopes‐VirellaMF , HuntKJ , BakerNL , VirellaG , MoritzT , VADT Investigators. The levels of MDA‐LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis2012;224(2):526‐31. [MEDLINE: 22963984] MeyersCD , McCarrenM , WongND , AbrairaC , DuckworthWC , KashyapML , et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology2006;98(1):63‐5. [MEDLINE: 16784922] MoritzT , DuckworthW , AbrairaC . Veterans Affairs diabetes trial‐‐corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129‐39; PMID: 19092145]. New England Journal of Medicine2009;361(10):1024‐5. [MEDLINE: 19726779] ReavenPD , EmanueleN , MoritzT , KleinR , DavisM , GlanderK , et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2008;31(5):952‐7. [MEDLINE: 18316393] ReavenPD , MoritzTE , SchwenkeDC , AndersonRJ , CriquiM , DetranoR , et al. Intensive glucose‐lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes2009;58(11):2642‐8. [MEDLINE: 19651816] SaremiA , AndersonRJ , LuoP , MoritzTE , SchwenkeDC , AllisonM , et al. Association between IL‐6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis2009;203(2):610‐4. [MEDLINE: 18804762] SaremiA , BahnG , ReavenPD , VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2012;35(11):2390‐2. [MEDLINE: 22875226] SaremiA , MoritzTE , AndersonRJ , AbrairaC , DuckworthWC , ReavenPD , et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care2010;33(12):2642‐7. [MEDLINE: 20807873] SaremiA , SchwenkeDC , BahnG , GeL , EmanueleN , ReavenPD , et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2015;64(2):218‐25. [MEDLINE: 25456099] ZimeringMB , AndersonRJ , GeL , MoritzTE , Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical &amp; Experimental2011;60(2):284‐91. [MEDLINE: 20206949] ZimeringMB , AndersonRJ , LuoP , MoritzTE , Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor‐1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2008;57(11):1563‐9. [MEDLINE: 18940395] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(6):882‐7. [MEDLINE: 19375761] ZimeringMB , AndersonRJ , MoritzTE , GeL , Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical &amp; Experimental2009;58(3):393‐400. [MEDLINE: 19217457] ZimeringMB , PanZ . Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology &amp; Metabolism2009;94(6):2171‐7. [MEDLINE: 19293267] ">VADT Study 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1566 any hypoglycaemia/100 patient‐year</p> <p>12 major hypoglycaemia/100 patient‐year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432 any hypoglycaemia/100 patient‐year</p> <p>4 major hypoglycaemia/100 patient‐year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &lt; 0.001</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Narrative table for hypoglycaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/full#CD010137-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010137-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tight versus non‐tight glycaemic control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Doubling serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.64, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Development ESKD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.34, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.73, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sudden death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.26, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.76, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.71, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.67, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Non‐fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.68, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Onset microalbuminuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Progression of microalbuminuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.38, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Regression of albuminuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [‐0.42, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Glomerular filtration rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.86 [‐15.69, 5.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.38 [‐1.93, ‐0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tight versus non‐tight glycaemic control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010137-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tight versus non‐tight glycaemic control (subgroup analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cardiovascular mortality (age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 &lt; 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.37, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 &gt; 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.71, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular mortality (allocation concealment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.17, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.74, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular mortality (duration of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 &lt; 60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.04, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 &gt; 60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.78, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cardiovascular mortality (GFR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 &lt; 90 mL/min/1.73 m²</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.17, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 &gt; 90 mL/min/1.73 m²</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.90, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality (age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 &lt; 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.65, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 &gt; 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.89, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause mortality (allocation concealment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.15, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All‐cause mortality (duration of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 &lt; 60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.03, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 &gt; 60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality (GFR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 &lt; 90 mL/min/1.73 m²</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.15, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 &gt; 90 mL/min/1.73 m²</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.60, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Non‐fatal myocardial infarction (age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 &lt; 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.21, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 &gt; 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Non‐fatal myocardial infarction (allocation concealment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.67, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Non‐fatal myocardial infarction (duration of treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 &lt; 60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.65, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 &gt; 60 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.57, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Non‐fatal myocardial infarction (GFR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 &lt; 90 mL/min/1.73 m²</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 &gt; 90 mL/min/1.73 m²</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.21, 1.39]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tight versus non‐tight glycaemic control (subgroup analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010137.pub2/references#CD010137-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010137.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010137-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010137-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010137-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010137-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD010137-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010137-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010137\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010137\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010137\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010137\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010137\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010137.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010137.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010137.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010137.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010137.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727275383"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010137.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727275389"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010137.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea8159a229377',t:'MTc0MDcyNzI3NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 